Induction	O
of	O
bcl-2	B-protein
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B-cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

Levels	O
of	O
bcl-2	B-RNA
mRNA	I-RNA
and	O
protein	O
increase	O
with	O
cross-linking	O
of	O
surface	B-protein
immunoglobulin	I-protein
.	O

We	O
have	O
located	O
the	O
major	O
positive	O
regulatory	O
region	O
for	O
control	O
of	O
bcl-2	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
.	O

The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	B-DNA
and	I-DNA
a	I-DNA
downstream	I-DNA
regulatory	I-DNA
region	I-DNA
.	O

The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	B-DNA
AMP-responsive	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross-linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

Mutations	O
of	O
the	O
CRE	B-DNA
site	I-DNA
that	O
result	O
in	O
loss	O
of	O
CREB	B-protein
binding	O
also	O
lead	O
to	O
loss	O
of	O
functional	O
activity	O
of	O
the	O
bcl-2	O
promoter	O
in	O
transient-transfection	O
assays	O
.	O

The	O
presence	O
of	O
an	O
active	O
CRE	B-DNA
site	I-DNA
in	O
the	O
bcl-2	B-DNA
promoter	I-DNA
implies	O
that	O
the	O
regulation	O
of	O
bcl-2	B-protein
expression	O
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Treatment	O
of	O
the	O
mature	B-cell_line
B-cell	I-cell_line
line	I-cell_line
BAL-17	I-cell_line
with	O
either	O
anti-immunoglobulin	O
M	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
leads	O
to	O
an	O
increase	O
in	O
bcl-2	B-protein
expression	O
that	O
is	O
mediated	O
by	O
the	O
CRE	B-DNA
site	I-DNA
.	O

Treatment	O
of	O
the	O
more	O
immature	B-cell_line
B-cell	I-cell_line
line	I-cell_line
,	O
Ramos	B-cell_line
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium-dependent	O
apoptosis	O
.	O

bcl-2	B-protein
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	B-DNA
site	I-DNA
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O

The	O
phosphorylation	O
of	O
CREB	B-protein
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
rather	O
than	O
by	O
protein	B-protein
kinase	I-protein
A	I-protein
.	O

Although	O
the	O
CRE	B-DNA
site	I-DNA
is	O
necessary	O
,	O
optimal	O
induction	O
of	O
bcl-2	B-protein
expression	O
requires	O
participation	O
of	O
the	O
upstream	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	B-protein
alters	O
its	O
interaction	O
with	O
the	O
upstream	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

The	O
CRE	B-DNA
site	I-DNA
in	O
the	O
bcl-2	B-DNA
promoter	I-DNA
appears	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
induction	O
of	O
bcl-2	B-protein
expression	O
during	O
the	O
activation	O
of	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
during	O
the	O
rescue	O
of	O
immature	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	B-DNA
site	I-DNA
is	O
responsible	O
for	O
induction	O
of	O
bcl-2	B-protein
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLoGY	NULL
,	NULL
Oct.	NULL
1996	NULL
,	NULL
p.	NULL
5546-5556	NULL
0270-7306/96/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
Â©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

16	NULL
,	NULL
No	NULL
.	NULL

10	NULL
Induction	NULL
of	NULL
be/-2	NULL
Expression	NULL
by	NULL
Phosphorylated	NULL
CREB	NULL
Proteins	NULL
during	NULL
B-Cell	NULL
Activation	NULL
and	NULL
Rescue	NULL
from	NULL
Apoptosis	NULL
BYRON	NULL
E.	NULL
WILSON	NULL
,	NULL
EVONNE	NULL
MOCHON	NULL
,	NULL
anp	NULL
LINDA	NULL
M.	NULL
BOXER*	NULL
Center	NULL
for	NULL
Molecular	NULL
Biology	NULL
in	NULL
Medicine	NULL
,	NULL
Palo	NULL
Alto	NULL
Veterans	NULL
Affairs	NULL
Medical	NULL
Center	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
California	NULL
94305	NULL
Received	NULL
29	NULL
March	NULL
1996/Returned	NULL
for	NULL
modification	NULL
27	NULL
May	NULL
1996/Accepted	NULL
11	NULL
July	NULL
1996	NULL
Engagement	NULL
of	NULL
surface	NULL
immunoglobulin	NULL
on	NULL
mature	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
rescue	NULL
from	NULL
apoptosis	NULL
and	NULL
to	NULL
proliferation	NULL
.	NULL

Levels	NULL
of	NULL
be/-2	NULL
mRNA	NULL
and	NULL
protein	NULL
increase	NULL
with	NULL
cross-linking	NULL
of	NULL
surface	NULL
immunoglobulin	NULL
.	NULL

We	NULL
have	NULL
located	NULL
the	NULL
major	NULL
positive	NULL
regulatory	NULL
region	NULL
for	NULL
control	NULL
of	NULL
be/-2	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
in	NULL
the	NULL
5	NULL
'	NULL
-flanking	NULL
region	NULL
.	NULL

The	NULL
positive	NULL
region	NULL
can	NULL
be	NULL
divided	NULL
into	NULL
an	NULL
upstream	NULL
and	NULL
a	NULL
downstream	NULL
regulatory	NULL
region	NULL
.	NULL

The	NULL
downstream	NULL
regulatory	NULL
region	NULL
contains	NULL
a	NULL
cyclic	NULL
AMP-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
.	NULL

We	NULL
show	NULL
by	NULL
antibody	NULL
supershift	NULL
experiments	NULL
and	NULL
UV	NULL
cross-linking	NULL
followed	NULL
by	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
that	NULL
both	NULL
CREB	NULL
and	NULL
ATF	NULL
family	NULL
members	NULL
bind	NULL
to	NULL
this	NULL
region	NULL
in	NULL
vitro	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
CRE	NULL
site	NULL
that	NULL
result	NULL
in	NULL
loss	NULL
of	NULL
CREB	NULL
binding	NULL
also	NULL
lead	NULL
to	NULL
loss	NULL
of	NULL
functional	NULL
activity	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
in	NULL
transient-transfection	NULL
assays	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
an	NULL
active	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
be/-2	NULL
promoter	NULL
implies	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
be/-2	NULL
expression	NULL
is	NULL
linked	NULL
to	NULL
a	NULL
signal	NULL
transduction	NULL
pathway	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
mature	NULL
B-cell	NULL
line	NULL
BAL-17	NULL
with	NULL
either	NULL
anti-immunoglobulin	NULL
M	NULL
or	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
leads	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
be/-2	NULL
expression	NULL
that	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
CRE	NULL
site	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
more	NULL
immature	NULL
B-cell	NULL
line	NULL
,	NULL
Ramos	NULL
,	NULL
with	NULL
phorbol	NULL
esters	NULL
rescues	NULL
the	NULL
cells	NULL
from	NULL
calcium-dependent	NULL
apoptosis	NULL
.	NULL

be/-2	NULL
expression	NULL
is	NULL
increased	NULL
following	NULL
phorbol	NULL
ester	NULL
treatment	NULL
,	NULL
and	NULL
the	NULL
increased	NULL
expression	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
CRE	NULL
site	NULL
.	NULL

These	NULL
stimuli	NULL
result	NULL
in	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
.	NULL

The	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
that	NULL
results	NULL
in	NULL
activation	NULL
is	NULL
mediated	NULL
by	NULL
protein	NULL
kinase	NULL
C	NULL
rather	NULL
than	NULL
by	NULL
protein	NULL
kinase	NULL
A	NULL
.	NULL

Although	NULL
the	NULL
CRE	NULL
site	NULL
is	NULL
necessary	NULL
,	NULL
optimal	NULL
induction	NULL
of	NULL
be/-2	NULL
expression	NULL
requires	NULL
participation	NULL
of	NULL
the	NULL
upstream	NULL
regulatory	NULL
element	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
alters	NULL
its	NULL
interaction	NULL
with	NULL
the	NULL
upstream	NULL
regulatory	NULL
element	NULL
.	NULL

The	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
be/-2	NULL
promoter	NULL
appears	NULL
to	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
bel-2	NULL
expression	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
mature	NULL
B	NULL
cells	NULL
and	NULL
during	NULL
the	NULL
rescue	NULL
of	NULL
immature	NULL
B	NULL
cells	NULL
from	NULL
apoptosis	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
CRE	NULL
site	NULL
is	NULL
responsible	NULL
for	NULL
induction	NULL
of	NULL
be/-2	NULL
expression	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
particularly	NULL
those	NULL
in	NULL
which	NULL
protein	NULL
kinase	NULL
C	NULL
is	NULL
involved	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
a	NULL
humoral	NULL
immune	NULL
response	NULL
is	NULL
complex	NULL
.	NULL

It	NULL
involves	NULL
initial	NULL
activation	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
subsequent	NULL
proliferation	NULL
of	NULL
the	NULL
activated	NULL
precursors	NULL
,	NULL
and	NULL
differentiation	NULL
of	NULL
the	NULL
activated	NULL
cells	NULL
into	NULL
mature	NULL
immunoglobulin-secreting	NULL
cells	NULL
.	NULL

The	NULL
process	NULL
of	NULL
differentiation	NULL
has	NULL
been	NULL
studied	NULL
by	NULL
using	NULL
Staphylococcus	NULL
aureus	NULL
Cowan	NULL
1	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
antigen	NULL
receptor	NULL
because	NULL
it	NULL
can	NULL
induce	NULL
B-cell	NULL
DNA	NULL
synthesis	NULL
in	NULL
a	NULL
T-cell-inde-pendent	NULL
manner	NULL
(	NULL
16	NULL
,	NULL
48	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
many	NULL
changes	NULL
in	NULL
gene	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
is	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
bei-2	NULL
at	NULL
the	NULL
mRNA	NULL
level	NULL
(	NULL
22	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Engagement	NULL
of	NULL
the	NULL
B-cell	NULL
antigen	NULL
receptor	NULL
leads	NULL
to	NULL
differing	NULL
outcomes	NULL
depending	NULL
on	NULL
the	NULL
stage	NULL
of	NULL
development	NULL
of	NULL
the	NULL
B	NULL
cell	NULL
.	NULL

Apoptosis	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
this	NULL
process	NULL
.	NULL

In	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
self-reactive	NULL
immature	NULL
surface	NULL
IgM	NULL
*	NULL
IgD~	NULL
B	NULL
cells	NULL
are	NULL
eliminated	NULL
by	NULL
apoptosis	NULL
;	NULL
this	NULL
process	NULL
leads	NULL
to	NULL
induction	NULL
of	NULL
tolerance	NULL
.	NULL

At	NULL
the	NULL
pro-B-cell	NULL
stage	NULL
,	NULL
as	NULL
immunoglobulin	NULL
(	NULL
Ig	NULL
)	NULL
gene	NULL
rearrangement	NULL
is	NULL
occurring	NULL
,	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
cells	NULL
die	NULL
by	NULL
apoptosis	NULL
.	NULL

Binding	NULL
of	NULL
antigen	NULL
to	NULL
the	NULL
antigen	NULL
receptor	NULL
in	NULL
immature	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
death	NULL
by	NULL
apoptosis	NULL
(	NULL
13	NULL
,	NULL
26	NULL
)	NULL
.	NULL

In	NULL
cell	NULL
line	NULL
models	NULL
,	NULL
this	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
level	NULL
of	NULL
bel-2	NULL
mRNA	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Anti-CD40	NULL
antibodies	NULL
protect	NULL
against	NULL
apoptosis	NULL
and	NULL
result	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
be/-2	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Apoptosis	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
mature	NULL
lym-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Hematology	NULL
,	NULL
S-161	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
94305-5112	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
415	NULL
)	NULL
493-5000	NULL
,	NULL
ext	NULL
.	NULL

63126	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
415	NULL
)	NULL
858-3982	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
hf.Imb	NULL
@	NULL
forsythe.stanford.edu	NULL
.	NULL

5546	NULL
phocytes	NULL
.	NULL

In	NULL
the	NULL
germinal	NULL
centers	NULL
,	NULL
widespread	NULL
apoptosis	NULL
is	NULL
observed	NULL
.	NULL

Engagement	NULL
of	NULL
surface	NULL
Ig	NULL
leads	NULL
to	NULL
rescue	NULL
from	NULL
apoptosis	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
be/-2	NULL
is	NULL
observed	NULL
when	NULL
germinal-center	NULL
cells	NULL
are	NULL
prevented	NULL
from	NULL
undergoing	NULL
apoptosis	NULL
(	NULL
33	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
antigen	NULL
to	NULL
the	NULL
B-cell	NULL
receptor	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
proliferation	NULL
.	NULL

Binding	NULL
of	NULL
antigen	NULL
to	NULL
the	NULL
B-cell	NULL
receptor	NULL
on	NULL
either	NULL
germinal-center	NULL
cells	NULL
or	NULL
resting	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
a	NULL
similar	NULL
pattern	NULL
of	NULL
second-messenger	NULL
induction	NULL
,	NULL
including	NULL
activation	NULL
of	NULL
Sre	NULL
and	NULL
Sre-related	NULL
protein	NULL
kinases	NULL
(	NULL
4	NULL
,	NULL
60	NULL
)	NULL
,	NULL
phosphorylation	NULL
on	NULL
tyrosine	NULL
residues	NULL
of	NULL
a	NULL
number	NULL
of	NULL
substrates	NULL
(	NULL
3	NULL
,	NULL
6	NULL
,	NULL
20	NULL
,	NULL
31	NULL
)	NULL
,	NULL
engagement	NULL
of	NULL
G	NULL
proteins	NULL
(	NULL
19	NULL
,	NULL
25	NULL
,	NULL
39	NULL
)	NULL
,	NULL
increased	NULL
inositol	NULL
1,4,5-triphosphate	NULL
levels	NULL
,	NULL
increased	NULL
intracellular	NULL
calcium	NULL
levels	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
(	NULL
5	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
PKC	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
NF-kB	NULL
and	NULL
AP-1	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
10	NULL
,	NULL
34	NULL
,	NULL
54	NULL
)	NULL
.	NULL

Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
undergo	NULL
apoptosis	NULL
after	NULL
ligation	NULL
of	NULL
surface	NULL
IgM	NULL
or	NULL
treatment	NULL
with	NULL
a	NULL
calcium	NULL
ionophore	NULL
(	NULL
2	NULL
,	NULL
7	NULL
,	NULL
18	NULL
,	NULL
23	NULL
,	NULL
28	NULL
,	NULL
53	NULL
)	NULL
.	NULL

Group	NULL
I	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
display	NULL
a	NULL
surface	NULL
phenotype	NULL
characteristic	NULL
of	NULL
germinal-center	NULL
cells	NULL
,	NULL
and	NULL
they	NULL
have	NULL
been	NULL
used	NULL
as	NULL
a	NULL
model	NULL
for	NULL
germinal-center	NULL
B	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
PKC	NULL
by	NULL
phorbol	NULL
esters	NULL
reduces	NULL
apoptosis	NULL
induced	NULL
by	NULL
calcium	NULL
ionophores	NULL
or	NULL
surface	NULL
IgM	NULL
ligation	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Apoptosis	NULL
can	NULL
also	NULL
be	NULL
triggered	NULL
by	NULL
inhibitors	NULL
of	NULL
PKC	NULL
.	NULL

High-level	NULL
expression	NULL
of	NULL
Bel-2	NULL
protects	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
ionomycin	NULL
or	NULL
surface	NULL
IgM	NULL
cross-linking	NULL
(	NULL
28	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
causes	NULL
an	NULL
up-regulation	NULL
of	NULL
be/-2	NULL
mRNA	NULL
and	NULL
protein	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
protects	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
lines	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
ionomycin	NULL
by	NULL
up-regulation	NULL
of	NULL
bel-2	NULL
by	NULL
a	NULL
mechanism	NULL
that	NULL
is	NULL
dependent	NULL
on	NULL
PKC	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
major	NULL
transcriptional	NULL
promoter	NULL
for	NULL
bei-2	NULL
,	NULL
P1	NULL
,	NULL
is	NULL
located	NULL
1,386	NULL
to	NULL
1,423	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
(	NULL
50	NULL
)	NULL
.	NULL

This	NULL
is	NULL
a	NULL
TATA-less	NULL
,	NULL
GC-rich	NULL
promoter	NULL
that	NULL
displays	NULL
multiple	NULL
transcription	NULL
state	NULL
sites	NULL
.	NULL

A	NULL
minor	NULL
promoter	NULL
,	NULL
P2	NULL
,	NULL
which	NULL
is	NULL
used	NULL
in	NULL
some	NULL
cell	NULL
types	NULL
,	NULL
is	NULL
located	NULL
1.3	NULL
kb	NULL
downstream	NULL
from	NULL
the	NULL
first	NULL
one	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Little	NULL
information	NULL
is	NULL
available	NULL
concerning	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
be/-2	NULL
gene	NULL
.	NULL

A	NULL
negative	NULL
regulatory	NULL
element	NULL
upstream	NULL
of	NULL
the	NULL
P2	NULL
promoter	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
61	NULL
)	NULL
.	NULL

The	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
this	NULL
element	NULL
have	NULL
not	NULL
been	NULL
identified	NULL
,	NULL
although	NULL
p53	NULL
was	NULL
shown	NULL
to	NULL
mediate	NULL
downregu-lation	NULL
of	NULL
be/-2	NULL
either	NULL
directly	NULL
or	NULL
indirectly	NULL
through	NULL
a	NULL
195-bp	NULL
fragment	NULL
of	NULL
this	NULL
region	NULL
(	NULL
37	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
described	NULL
three	NULL
sites	NULL
which	NULL
are	NULL
negative	NULL
regulators	NULL
of	NULL
be/-2	NULL
expression	NULL
in	NULL
pre-B	NULL
cells	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Normal	NULL
pre-B	NULL
cells	NULL
express	NULL
very	NULL
little	NULL
be/-2	NULL
,	NULL
and	NULL
extensive	NULL
cell	NULL
death	NULL
by	NULL
apoptosis	NULL
occurs	NULL
at	NULL
this	NULL
developmental	NULL
stage	NULL
.	NULL

Bel-2	NULL
protein	NULL
levels	NULL
are	NULL
increased	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
the	NULL
three	NULL
#	NULL
1	NULL
sites	NULL
are	NULL
not	NULL
functional	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
(	NULL
8	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
characterize	NULL
the	NULL
regulatory	NULL
regions	NULL
,	NULL
including	NULL
a	NULL
cyclic	NULL
AMP	NULL
(	NULL
cAMP	NULL
)	NULL
-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
,	NULL
that	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
positive	NULL
regulation	NULL
of	NULL
be/-2	NULL
expression	NULL
in	NULL
both	NULL
pre-B	NULL
cells	NULL
and	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

Elevation	NULL
of	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
can	NULL
result	NULL
in	NULL
either	NULL
stimulation	NULL
or	NULL
repression	NULL
of	NULL
specific	NULL
gene	NULL
expression	NULL
;	NULL
most	NULL
of	NULL
these	NULL
genes	NULL
contain	NULL
one	NULL
or	NULL
more	NULL
CREs	NULL
.	NULL

The	NULL
consensus	NULL
CRE	NULL
sequence	NULL
is	NULL
GTGACGTCA	NULL
.	NULL

cAMP	NULL
binds	NULL
to	NULL
the	NULL
regulatory	NULL
subunit	NULL
of	NULL
PKA	NULL
and	NULL
releases	NULL
the	NULL
active	NULL
catalytic	NULL
subunit	NULL
.	NULL

This	NULL
subunit	NULL
phosphorylates	NULL
the	NULL
transactivation	NULL
domain	NULL
of	NULL
CRE-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
,	NULL
which	NULL
then	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
containing	NULL
CREs	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
phosphoacceptor	NULL
site	NULL
(	NULL
Ser-133	NULL
)	NULL
results	NULL
in	NULL
a	NULL
dominant	NULL
negative	NULL
form	NULL
of	NULL
CREB	NULL
(	NULL
1	NULL
,	NULL
51	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
CREBs	NULL
,	NULL
including	NULL
CREB	NULL
,	NULL
CRE	NULL
modulator	NULL
,	NULL
and	NULL
several	NULL
activating	NULL
transcription	NULL
factors	NULL
(	NULL
ATFs	NULL
)	NULL
,	NULL
have	NULL
been	NULL
de-scribed	NULL
.	NULL

The	NULL
CREBs	NULL
are	NULL
basic	NULL
leucine	NULL
zipper	NULL
transcription	NULL
factors	NULL
and	NULL
are	NULL
active	NULL
as	NULL
either	NULL
homo-	NULL
or	NULL
heterodimers	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
ATFs	NULL
heterodimerize	NULL
with	NULL
members	NULL
of	NULL
the	NULL
Jun/Fos	NULL
family	NULL
of	NULL
proteins	NULL
(	NULL
for	NULL
reviews	NULL
,	NULL
see	NULL
references	NULL
30	NULL
,	NULL
32	NULL
,	NULL
and	NULL
36	NULL
)	NULL
.	NULL

We	NULL
have	NULL
elucidated	NULL
the	NULL
mechanism	NULL
of	NULL
increased	NULL
bel-2	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
and	NULL
during	NULL
rescue	NULL
from	NULL
calcium-dependent	NULL
apoptosis	NULL
of	NULL
immature	NULL
B	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
a	NULL
CRE	NULL
mediates	NULL
the	NULL
increase	NULL
in	NULL
be/-2	NULL
expression	NULL
following	NULL
surface	NULL
Ig	NULL
cross-linking	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
or	NULL
treatment	NULL
with	NULL
phorbol	NULL
esters	NULL
in	NULL
both	NULL
mature	NULL
and	NULL
immature	NULL
B	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
present	NULL
evidence	NULL
that	NULL
PKC	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
CREB	NULL
by	NULL
phosphorylation	NULL
.	NULL

Optimal	NULL
bel-2	NULL
activation	NULL
occurs	NULL
when	NULL
the	NULL
phosphorylated	NULL
CREB	NULL
interacts	NULL
with	NULL
an	NULL
upstream	NULL
regulatory	NULL
region	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
changes	NULL
the	NULL
interaction	NULL
of	NULL
CREB	NULL
with	NULL
neighboring	NULL
promoter	NULL
elements	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Plasmid	NULL
constructs	NULL
.	NULL

A	NULL
DNA	NULL
fragment	NULL
from	NULL
BamHI	NULL
(	NULL
-3934	NULL
)	NULL
to	NULL
Secl	NULL
(	NULL
-1287	NULL
)	NULL
of	NULL
the	NULL
human	NULL
be/-2	NULL
gene	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Michael	NULL
Cleary	NULL
,	NULL
Stanford	NULL
Uni-versity	NULL
)	NULL
was	NULL
inserted	NULL
into	NULL
a	NULL
luciferase	NULL
reporter	NULL
vector	NULL
with	NULL
Psfl	NULL
linkers	NULL
.	NULL

Numbering	NULL
of	NULL
the	NULL
bel-2	NULL
sequence	NULL
is	NULL
relative	NULL
to	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
.	NULL

Progressive	NULL
5	NULL
'	NULL
truncations	NULL
of	NULL
the	NULL
be/-2	NULL
sequence	NULL
by	NULL
restriction	NULL
digestion	NULL
gave	NULL
rise	NULL
to	NULL
constructs	NULL
spanning	NULL
the	NULL
sequence	NULL
from	NULL
Sacl	NULL
(	NULL
-1287	NULL
)	NULL
to	NULL
Xhol	NULL
(	NULL
-2857	NULL
)	NULL
,	NULL
Avril	NULL
(	NULL
-2337	NULL
)	NULL
,	NULL
Nof	NULL
(	NULL
-1794	NULL
)	NULL
,	NULL
SacII	NULL
(	NULL
-1743	NULL
)	NULL
,	NULL
SaclI	NULL
(	NULL
-1693	NULL
)	NULL
,	NULL
SaclII	NULL
(	NULL
-1640	NULL
)	NULL
,	NULL
BsrFI	NULL
(	NULL
-1526	NULL
)	NULL
,	NULL
and	NULL
Apal	NULL
(	NULL
-1337	NULL
)	NULL
.	NULL

Additional	NULL
5	NULL
'	NULL
truncations	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
subfragment	NULL
cloning	NULL
to	NULL
form	NULL
constructs	NULL
spanning	NULL
the	NULL
sequence	NULL
from	NULL
Secl	NULL
(	NULL
-1287	NULL
)	NULL
to	NULL
introduced	NULL
BamHI	NULL
sites	NULL
at	NULL
-1473	NULL
and	NULL
-1413	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

To	NULL
study	NULL
the	NULL
activity	NULL
observed	NULL
between	NULL
SeclI	NULL
(	NULL
-1640	NULL
)	NULL
and	NULL
BsrFI	NULL
(	NULL
-1526	NULL
)	NULL
in	NULL
more	NULL
detail	NULL
,	NULL
subfragments	NULL
of	NULL
this	NULL
area	NULL
generated	NULL
by	NULL
PCR	NULL
cloning	NULL
or	NULL
oligonucleotide	NULL
synthesis	NULL
were	NULL
inserted	NULL
into	NULL
a	NULL
polylinker	NULL
at	NULL
the	NULL
BsrFI	NULL
site	NULL
in	NULL
the	NULL
-1526-bel-2	NULL
plasmid	NULL
constructed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Progressive	NULL
5'-subfragment	NULL
truncations	NULL
spanning	NULL
from	NULL
-1526	NULL
to	NULL
-1640	NULL
,	NULL
to	NULL
-1611	NULL
,	NULL
to	NULL
-1578	NULL
,	NULL
to	NULL
-1564	NULL
,	NULL
and	NULL
to	NULL
INDUCTION	NULL
OF	NULL
be/-2	NULL
BY	NULL
CREB	NULL
PROTEINS	NULL
5547	NULL
-1552	NULL
were	NULL
inserted	NULL
in	NULL
this	NULL
polylinker	NULL
.	NULL

Interposition	NULL
of	NULL
the	NULL
polylinker	NULL
between	NULL
contiguous	NULL
be/-2	NULL
sequences	NULL
at	NULL
site	NULL
-1526	NULL
did	NULL
not	NULL
alter	NULL
promoter	NULL
activity	NULL
when	NULL
compared	NULL
with	NULL
analogous	NULL
controls	NULL
without	NULL
polylinker	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
plasmid	NULL
containing	NULL
the	NULL
wild-type	NULL
upstream	NULL
regulatory	NULL
element	NULL
(	NULL
WiURE	NULL
)	NULL
was	NULL
constructed	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
by	NULL
inserting	NULL
the	NULL
PCR-cloned	NULL
sequence	NULL
-1640	NULL
to	NULL
-1544	NULL
in	NULL
the	NULL
polylinker	NULL
5	NULL
``	NULL
of	NULL
the	NULL
-1526-bcf-2	NULL
plasmid	NULL
.	NULL

A	NULL
plasmid	NULL
containing	NULL
the	NULL
wild-type	NULL
downstream	NULL
regulatory	NULL
element	NULL
(	NULL
WtDRE	NULL
)	NULL
,	NULL
including	NULL
the	NULL
endogenous	NULL
bel-2	NULL
CRE	NULL
site	NULL
,	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
the	NULL
synthesized	NULL
oligonucleotide	NULL
sequence	NULL
-1552	NULL
through	NULL
-1535	NULL
in	NULL
the	NULL
polylinker	NULL
5	NULL
``	NULL
of	NULL
the	NULL
-1526-bcf-2	NULL
plasmid	NULL
.	NULL

Plasmids	NULL
with	NULL
mutations	NULL
in	NULL
and	NULL
near	NULL
the	NULL
CRE	NULL
site	NULL
were	NULL
constructed	NULL
similarly	NULL
with	NULL
the	NULL
sequences	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

The	NULL
following	NULL
base	NULL
pairs	NULL
were	NULL
mutated	NULL
(	NULL
with	NULL
plasmid	NULL
name	NULL
in	NULL
parentheses	NULL
)	NULL
:	NULL
-1552	NULL
and	NULL
-1548	NULL
(	NULL
mC1,4	NULL
)	NULL
;	NULL
-1551	NULL
through	NULL
-1549	NULL
(	NULL
mC2-3	NULL
)	NULL
;	NULL
-1547	NULL
and	NULL
-1545	NULL
(	NULL
mC6,8	NULL
)	NULL
;	NULL
-1541	NULL
and	NULL
-1540	NULL
(	NULL
mC12,13	NULL
)	NULL
;	NULL
-1540	NULL
and	NULL
-1539	NULL
(	NULL
mCâ¬13,14	NULL
)	NULL
;	NULL
and	NULL
-1540	NULL
through	NULL
-1536	NULL
(	NULL
mC13-17	NULL
)	NULL
.	NULL

A	NULL
construct	NULL
(	NULL
MutCRE	NULL
)	NULL
with	NULL
the	NULL
CRE	NULL
site	NULL
changed	NULL
from	NULL
GTGACGTTA	NULL
to	NULL
GTGAA	NULL
TTTA	NULL
was	NULL
prepared	NULL
from	NULL
the	NULL
-1640	NULL
construct	NULL
with	NULL
the	NULL
Quikchange	NULL
site-directed	NULL
mutagenesis	NULL
kit	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

A	NULL
construct	NULL
containing	NULL
two	NULL
CRE	NULL
sites	NULL
was	NULL
prepared	NULL
by	NULL
inserting	NULL
CRE	NULL
oligonucleotides	NULL
with	NULL
Sa/l	NULL
and	NULL
Xhol	NULL
ends	NULL
into	NULL
the	NULL
Sa/l	NULL
site	NULL
of	NULL
the	NULL
pGL2	NULL
promoter	NULL
,	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
construct	NULL
containing	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
Ig	NULL
heavy-chain	NULL
enhancer	NULL
l	NULL
site	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
)	NULL
.	NULL

All	NULL
plasmid	NULL
sequences	NULL
were	NULL
confirmed	NULL
by	NULL
the	NULL
dideoxynucleotide	NULL
method	NULL
(	NULL
Sequenase	NULL
;	NULL
U.S.	NULL
Biochemical	NULL
)	NULL
.	NULL

The	NULL
CRE-dependent	NULL
plasmid	NULL
(	NULL
Bg/ll	NULL
CAT	NULL
)	NULL
and	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
(	NULL
RSV	NULL
)	NULL
CREB	NULL
and	NULL
RSV	NULL
CREB	NULL
M1	NULL
were	NULL
obtained	NULL
from	NULL
Marc	NULL
Montminy	NULL
,	NULL
Salk	NULL
Institute	NULL
.	NULL

The	NULL
Bg/II	NULL
CAT	NULL
construct	NULL
contains	NULL
the	NULL
somatostatin	NULL
gene	NULL
promoter	NULL
from	NULL
-71	NULL
to	NULL
+53	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
reporter	NULL
gene	NULL
(	NULL
40	NULL
)	NULL
.	NULL

RSV	NULL
CREB	NULL
expresses	NULL
full-length	NULL
CREB	NULL
from	NULL
the	NULL
RSV	NULL
promoter	NULL
,	NULL
and	NULL
RSV	NULL
CREB	NULL
M1	NULL
expresses	NULL
full-length	NULL
CREB	NULL
with	NULL
serine	NULL
133	NULL
changed	NULL
to	NULL
alanine	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
and	NULL
transient-transfection	NULL
assays	NULL
.	NULL

Nall-1	NULL
,	NULL
a	NULL
human	NULL
pre-B-cell	NULL
line	NULL
,	NULL
and	NULL
DHL-9	NULL
,	NULL
a	NULL
human	NULL
mature	NULL
B-cell	NULL
line	NULL
,	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
pg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
1-glutamine	NULL
.	NULL

Neither	NULL
cell	NULL
line	NULL
has	NULL
a	NULL
translocation	NULL
involving	NULL
the	NULL
be/-2	NULL
locus	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
,	NULL
Ramos	NULL
,	NULL
was	NULL
grown	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

BAL-17	NULL
cells	NULL
,	NULL
a	NULL
murine	NULL
B-lymphoma	NULL
cell	NULL
line	NULL
,	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
William	NULL
Paul	NULL
and	NULL
Richard	NULL
Asofsky	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL

BAL-17	NULL
cells	NULL
are	NULL
a	NULL
model	NULL
for	NULL
mature	NULL
B	NULL
cells	NULL
and	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
pg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
10	NULL
%	NULL
NCTC	NULL
109	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
B-mercap-toethanol	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

DNA	NULL
transfections	NULL
were	NULL
performed	NULL
with	NULL
cells	NULL
in	NULL
the	NULL
log	NULL
phase	NULL
(	NULL
5	NULL
X	NULL
10Â°	NULL
to	NULL
6	NULL
X	NULL
10Â°	NULL
cells	NULL
per	NULL
ml	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
RPMI	NULL
medium	NULL
and	NULL
resuspended	NULL
at	NULL
3	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
per	NULL
ml	NULL
in	NULL
RPMI	NULL
medium	NULL
containing	NULL
26	NULL
pg	NULL
of	NULL
DEAE-dextran	NULL
per	NULL
ml	NULL
(	NULL
17	NULL
)	NULL
.	NULL

A	NULL
total	NULL
of	NULL
10	NULL
to	NULL
20	NULL
jg	NULL
of	NULL
plasmid	NULL
DNA	NULL
was	NULL
added	NULL
,	NULL
and	NULL
electroporation	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
Bio-Rad	NULL
gene	NULL
pulser	NULL
at	NULL
960	NULL
wF	NULL
and	NULL
350	NULL
mV	NULL
for	NULL
DHL-9	NULL
,	NULL
320	NULL
mV	NULL
for	NULL
Ramos	NULL
,	NULL
300	NULL
mV	NULL
for	NULL
Nall-1	NULL
,	NULL
or	NULL
400	NULL
mV	NULL
for	NULL
BAL-17	NULL
cells	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
25	NULL
ml	NULL
of	NULL
supplemented	NULL
RPMI	NULL
medium	NULL
for	NULL
48	NULL
h.	NULL
Reporter	NULL
gene	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
luciferase	NULL
assay	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
luminescence	NULL
was	NULL
quantitated	NULL
with	NULL
an	NULL
LKB	NULL
1251	NULL
luminometer	NULL
.	NULL

Variation	NULL
in	NULL
transfection	NULL
efficiency	NULL
was	NULL
controlled	NULL
for	NULL
by	NULL
cotransfection	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
an	NULL
RSV	NULL
long	NULL
terminal	NULL
repeat-B-galactosidase	NULL
or	NULL
a	NULL
simian	NULL
virus	NULL
40	NULL
promoter-B-galactosidase	NULL
plasmid	NULL
.	NULL

Each	NULL
assay	NULL
was	NULL
performed	NULL
at	NULL
least	NULL
three	NULL
times	NULL
in	NULL
duplicate	NULL
with	NULL
at	NULL
least	NULL
two	NULL
different	NULL
plasmid	NULL
preparations	NULL
.	NULL

The	NULL
normalized	NULL
mean	NULL
values	NULL
with	NULL
standard	NULL
deviations	NULL
were	NULL
plotted	NULL
or	NULL
reported	NULL
in	NULL
tabular	NULL
form	NULL
.	NULL

Phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
forskolin	NULL
,	NULL
ionomycin	NULL
,	NULL
or	NULL
goat	NULL
anti-mouse	NULL
IgM	NULL
was	NULL
added	NULL
at	NULL
the	NULL
concentrations	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

7C	NULL
,	NULL
8A	NULL
,	NULL
and	NULL
9C	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
18	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
and	NULL
8A	NULL
)	NULL
or	NULL
6	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

9C	NULL
)	NULL
.	NULL

EMSA	NULL
.	NULL

The	NULL
oligonucleotides	NULL
used	NULL
as	NULL
probes	NULL
for	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
of	NULL
the	NULL
CRE	NULL
region	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
CRE	NULL
consensus	NULL
oligonucleotide	NULL
was	NULL
GAACCGTGTGACGTC	NULL
ACGCG	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
5	NULL
'	NULL
overhangs	NULL
and	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
a-*	NULL
``	NULL
P	NULL
]	NULL
dCTP	NULL
and	NULL
Klenow	NULL
polymerase	NULL
.	NULL

Binding	NULL
conditions	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
12	NULL
mM	NULL
N-2-hydroxyethylpiperazine-V'-2-ethanesulfonic	NULL
acid	NULL
(	NULL
HEPES	NULL
;	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
4	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
100	NULL
mM	NULL
KCI	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
3	NULL
mg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
1	NULL
ng	NULL
(	NULL
10+	NULL
cpm	NULL
)	NULL
of	NULL
end-labeled	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
protein	NULL
from	NULL
crude	NULL
nuclear	NULL
extract	NULL
.	NULL

Leupeptin	NULL
(	NULL
0.3	NULL
ug/m1	NULL
)	NULL
,	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
5	NULL
mM	NULL
)	NULL
,	NULL
antipain	NULL
(	NULL
0.3	NULL
pg/ml	NULL
)	NULL
,	NULL
and	NULL
aprotinin	NULL
(	NULL
2	NULL
ug/l	NULL
)	NULL
were	NULL
included	NULL
in	NULL
all	NULL
nuclear	NULL
extract	NULL
buffers	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
excess	NULL
competitor	NULL
oligonucleotides	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Electrophoresis	NULL
was	NULL
performed	NULL
at	NULL
30	NULL
mA	NULL
at	NULL
4Â°C	NULL
in	NULL
a	NULL
0.5	NULL
%	NULL
Tris	NULL
borate-EDTA-5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

For	NULL
the	NULL
supershift	NULL
EMSA	NULL
,	NULL
the	NULL
binding-reaction	NULL
mixture	NULL
was	NULL
incubated	NULL
with	NULL
antibody	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4Â°C	NULL
,	NULL
labeled	NULL
oligonucleotide	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Antibodies	NULL
specific	NULL
to	NULL
the	NULL
following	NULL
proteins	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
for	NULL
use	NULL
in	NULL
supershift	NULL
EMSA	NULL
:	NULL
ATF-1/CREB	NULL
(	NULL
recogniz-es	NULL
all	NULL
CREB/ATF	NULL
family	NULL
proteins	NULL
)	NULL
,	NULL
ATF-1/ATF-2	NULL
,	NULL
ATF-2	NULL
,	NULL
ATF-3	NULL
,	NULL
CREB-1	NULL
(	NULL
CREB	NULL
)	NULL
,	NULL
CREB-2	NULL
,	NULL
CREM-1	NULL
,	NULL
PEA3	NULL
,	NULL
c-jun	NULL
,	NULL
egr-1	NULL
,	NULL
etsl/ets2	NULL
,	NULL
and	NULL
c-fos	NULL
.	NULL

An	NULL
antibody	NULL
specific	NULL
for	NULL
the	NULL
phosphorylated	NULL
serine	NULL
133	NULL
form	NULL
of	NULL
CREB	NULL
was	NULL
obtained	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
Inc.	NULL
CREB	NULL
interactions	NULL
were	NULL
studied	NULL
by	NULL
addition	NULL
of	NULL
purified	NULL
truncated	NULL
CREB	NULL
(	NULL
CREB	NULL
bZIP	NULL
254-327	NULL
[	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
]	NULL
)	NULL
to	NULL
the	NULL
binding-reaction	NULL
mixture	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
labeled	NULL
oligonucleotide	NULL
.	NULL

5548	NULL
WILSON	NULL
ET	NULL
AL	NULL
.	NULL

UV	NULL
cross-linking	NULL
and	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

UV	NULL
cross-linking	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
11	NULL
)	NULL
with	NULL
a	NULL
short-wavelength	NULL
UV	NULL
light	NULL
box	NULL
at	NULL
4Â°C	NULL
for	NULL
60	NULL
min	NULL
.	NULL

An	NULL
autoradiograph	NULL
of	NULL
the	NULL
wet	NULL
gel	NULL
was	NULL
used	NULL
to	NULL
locate	NULL
the	NULL
EMSA	NULL
complexes	NULL
.	NULL

Regions	NULL
of	NULL
the	NULL
gel	NULL
containing	NULL
the	NULL
complexes	NULL
were	NULL
cut	NULL
out	NULL
,	NULL
and	NULL
the	NULL
individual	NULL
complexes	NULL
were	NULL
eluted	NULL
at	NULL
room	NULL
temperature	NULL
overnight	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-0.1	NULL
mM	NULL
EDTA-5	NULL
mM	NULL
dithiothreitol-150	NULL
mM	NULL
NaCl-0.1	NULL
mg	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
eluted	NULL
protein	NULL
was	NULL
precipitated	NULL
with	NULL
4	NULL
volumes	NULL
of	NULL
acetone	NULL
,	NULL
washed	NULL
with	NULL
ethanol	NULL
,	NULL
and	NULL
dried	NULL
.	NULL

It	NULL
was	NULL
then	NULL
resuspended	NULL
in	NULL
Laemmli	NULL
loading	NULL
buffer	NULL
,	NULL
and	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
was	NULL
performed	NULL
.	NULL

The	NULL
*Â°P-labeled	NULL
proteins	NULL
were	NULL
visualized	NULL
by	NULL
autoradiog-raphy	NULL
.	NULL

Methylation	NULL
interference	NULL
.	NULL

The	NULL
5'-end-labeled	NULL
oligonucleotide	NULL
(	NULL
either	NULL
WtDRE	NULL
or	NULL
bCREO	NULL
)	NULL
was	NULL
labeled	NULL
with	NULL
T4	NULL
kinase	NULL
and	NULL
methylated	NULL
with	NULL
0.5	NULL
%	NULL
dimethyl	NULL
sulfate	NULL
for	NULL
2	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
WtDRE	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
and	NULL
the	NULL
sequence	NULL
of	NULL
bCREO	NULL
was	NULL
GAACCGTGTGACACGA	NULL
.	NULL

These	NULL
oligonucleotides	NULL
were	NULL
used	NULL
in	NULL
EMSA	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
complexes	NULL
were	NULL
transferred	NULL
to	NULL
DEAE	NULL
membrane	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
exposed	NULL
to	NULL
film	NULL
to	NULL
locate	NULL
the	NULL
complexes	NULL
,	NULL
and	NULL
regions	NULL
containing	NULL
the	NULL
bound	NULL
and	NULL
free	NULL
probes	NULL
were	NULL
excised	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
eluted	NULL
and	NULL
cleaved	NULL
with	NULL
piperidine	NULL
,	NULL
and	NULL
equal	NULL
counts	NULL
of	NULL
bound	NULL
and	NULL
free	NULL
samples	NULL
were	NULL
resolved	NULL
in	NULL
a	NULL
15	NULL
%	NULL
acrylamide	NULL
sequencing	NULL
gel	NULL
.	NULL

S1	NULL
nuclease	NULL
protection	NULL
assay	NULL
.	NULL

BAL-17	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
medium	NULL
,	NULL
60	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
,	NULL
or	NULL
4	NULL
ug	NULL
of	NULL
anti-IgM	NULL
per	NULL
ml	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37Â°C	NULL
prior	NULL
to	NULL
isolation	NULL
of	NULL
RNA	NULL
by	NULL
the	NULL
guanidine	NULL
thiocyanate	NULL
method	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
be/-2	NULL
probe	NULL
(	NULL
41	NULL
)	NULL
and	NULL
a	NULL
1.8-kb	NULL
BamHI-HindIII	NULL
genomic	NULL
fragment	NULL
of	NULL
B	NULL
,	NULL
-microglobulin	NULL
end	NULL
labeled	NULL
at	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
exon	NULL
2	NULL
(	NULL
43	NULL
)	NULL
were	NULL
hybridized	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
total	NULL
RNA	NULL
for	NULL
16	NULL
h	NULL
at	NULL
55Â°C	NULL
.	NULL

Digestion	NULL
with	NULL
200	NULL
U	NULL
of	NULL
S1	NULL
nuclease	NULL
was	NULL
performed	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37Â°C	NULL
.	NULL

The	NULL
protected	NULL
fragments	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
6	NULL
%	NULL
sequencing	NULL
gel	NULL
.	NULL

DNA	NULL
fragmentation	NULL
analysis	NULL
.	NULL

Ramos	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10Â°	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
18	NULL
h	NULL
in	NULL
medium	NULL
with	NULL
no	NULL
addition	NULL
or	NULL
the	NULL
addition	NULL
of	NULL
1	NULL
g	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
,	NULL
or	NULL
both	NULL
ionomycin	NULL
and	NULL
PMA	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
,	NULL
centrifuged	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
20	NULL
pl	NULL
of	NULL
10	NULL
mM	NULL
EDTA-50	NULL
mM	NULL
Tris-HCI-0.5	NULL
%	NULL
sodium	NULL
N-lauroy	NULL
]	NULL
sarcosinate-0.5	NULL
ug	NULL
of	NULL
protease	NULL
K	NULL
per	NULL
ml	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
50Â°C	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37Â°C	NULL
after	NULL
addition	NULL
of	NULL
10	NULL
pl	NULL
of	NULL
RNase	NULL
A	NULL
(	NULL
100	NULL
pg/ml	NULL
!	NULL
)	NULL

and	NULL
then	NULL
incubated	NULL
for	NULL
5	NULL
min	NULL
at	NULL
70Â°C	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
mixed	NULL
with	NULL
10	NULL
pl	NULL
of	NULL
10	NULL
mM	NULL
EDTA	NULL
plus	NULL
1	NULL
%	NULL
low-melting-point	NULL
agarose	NULL
and	NULL
electrophoresed	NULL
in	NULL
40	NULL
mM	NULL
Tris-acetate-1	NULL
mM	NULL
EDTA	NULL
in	NULL
a	NULL
1.2	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

RESULTS	NULL
Identification	NULL
of	NULL
two	NULL
positive	NULL
regulatory	NULL
regions	NULL
in	NULL
the	NULL
bel-2	NULL
promoter	NULL
.	NULL

The	NULL
be/-2	NULL
major	NULL
transcriptional	NULL
promoter	NULL
,	NULL
P1	NULL
,	NULL
is	NULL
located	NULL
between	NULL
bp	NULL
-1390	NULL
and	NULL
-1440	NULL
upstream	NULL
from	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
(	NULL
50	NULL
)	NULL
.	NULL

bel-2	NULL
sequence	NULL
from	NULL
-3934	NULL
to	NULL
-1287	NULL
that	NULL
contains	NULL
the	NULL
P1	NULL
promoter	NULL
was	NULL
inserted	NULL
upstream	NULL
of	NULL
a	NULL
promoterless	NULL
luciferase	NULL
reporter	NULL
gene	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
and	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
DHL-9	NULL
cells	NULL
(	NULL
a	NULL
human	NULL
mature	NULL
B-cell	NULL
line	NULL
)	NULL
was	NULL
assessed	NULL
.	NULL

We	NULL
were	NULL
unable	NULL
to	NULL
demonstrate	NULL
any	NULL
transcript	NULL
initiation	NULL
at	NULL
the	NULL
P2	NULL
promoter	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Constructs	NULL
that	NULL
contained	NULL
both	NULL
the	NULL
P1	NULL
and	NULL
P2	NULL
promoters	NULL
yielded	NULL
similar	NULL
results	NULL
,	NULL
although	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
constructs	NULL
with	NULL
the	NULL
P2	NULL
promoter	NULL
was	NULL
much	NULL
lower	NULL
because	NULL
of	NULL
the	NULL
negative	NULL
regulatory	NULL
element	NULL
just	NULL
upstream	NULL
of	NULL
P2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
(	NULL
61	NULL
)	NULL
.	NULL

Progressive	NULL
5	NULL
'	NULL
truncations	NULL
of	NULL
the	NULL
be	NULL
!	NULL

-2	NULL
sequence	NULL
revealed	NULL
a	NULL
positive	NULL
regulatory	NULL
region	NULL
between	NULL
the	NULL
SaeclII	NULL
site	NULL
at	NULL
-1640	NULL
and	NULL
a	NULL
BsrFI	NULL
site	NULL
at	NULL
-1526	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

In	NULL
DHL-9	NULL
cells	NULL
,	NULL
this	NULL
area	NULL
resulted	NULL
in	NULL
a	NULL
3.8-fold	NULL
increase	NULL
in	NULL
reporter	NULL
gene	NULL
activity	NULL
over	NULL
the	NULL
basal	NULL
promoter	NULL
(	NULL
-1526	NULL
)	NULL
construct	NULL
.	NULL

This	NULL
appeared	NULL
to	NULL
be	NULL
the	NULL
only	NULL
positive	NULL
regulatory	NULL
region	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
pre-B-cell	NULL
line	NULL
,	NULL
Nall-1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
murine	NULL
and	NULL
human	NULL
be/-2	NULL
sequences	NULL
revealed	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
homol-ogy	NULL
in	NULL
this	NULL
area	NULL
.	NULL

To	NULL
study	NULL
the	NULL
activity	NULL
observed	NULL
between	NULL
SecII	NULL
(	NULL
-1640	NULL
)	NULL
and	NULL
BsrFI	NULL
(	NULL
-1526	NULL
)	NULL
in	NULL
more	NULL
detail	NULL
,	NULL
subfragments	NULL
of	NULL
this	NULL
area	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
BsrFI	NULL
(	NULL
-1526	NULL
)	NULL
site	NULL
.	NULL

Progressive	NULL
5	NULL
'	NULL
truncations	NULL
within	NULL
this	NULL
area	NULL
revealed	NULL
two	NULL
positive	NULL
regulatory	NULL
regions	NULL
in	NULL
DHL-9	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
DRE	NULL
,	NULL
located	NULL
between	NULL
-1552	NULL
and	NULL
-1526	NULL
,	NULL
was	NULL
responsible	NULL
for	NULL
a	NULL
1.5-fold	NULL
increase	NULL
in	NULL
basal	NULL
promoter	NULL
activity	NULL
over	NULL
that	NULL
obtained	NULL
with	NULL
a	NULL
P1	NULL
promoter	NULL
control	NULL
construct	NULL
.	NULL

This	NULL
activity	NULL
was	NULL
preserved	NULL
when	NULL
a	NULL
3	NULL
'	NULL
deletion	NULL
narrowed	NULL
this	NULL
element	NULL
to	NULL
-1552	NULL
through	NULL
-1534	NULL
.	NULL

The	NULL
remainder	NULL
of	NULL
the	NULL
positive	NULL
regulatory	NULL
activity	NULL
was	NULL
located	NULL
between	NULL
-1611	NULL
and	NULL
-1552	NULL
;	NULL
this	NULL
area	NULL
is	NULL
the	NULL
URE	NULL
.	NULL

Preliminary	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

-Not	NULL
|	NULL
i-	NULL
Sac	NULL
II	NULL
-	NULL
Sac	NULL
|	NULL
--	NULL
Bam	NULL
HI	NULL
bel-2	NULL
5Â°	NULL
promoter	NULL
region	NULL
|-|	NULL
luciferase	NULL
-	NULL
$	NULL
\	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
Gb	NULL
o	NULL
L	NULL
1.0	NULL
-	NULL
T	NULL
+4000	NULL
-3500	NULL
1500	NULL
1	NULL
T	NULL
*	NULL
I	NULL
I	NULL
-3000	NULL
-2500	NULL
-2000	NULL
B	NULL
|URE+DREH	NULL
basal	NULL
promoter	NULL
|-	NULL
Juciferase	NULL
&	NULL
I	NULL
I	NULL
[	NULL
8	NULL
Â§	NULL
--	NULL
_	NULL
Sac	NULL
II	NULL
BerF	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
1-0	NULL
I	NULL
I	NULL
W	NULL
I	NULL
*	NULL
U	NULL
*	NULL
U	NULL
Â®	NULL
T	NULL
~1650	NULL
-18630	NULL
-1610	NULL
1590	NULL
-1570	NULL
-1550	NULL
-1580	NULL
Termini	NULL
of	NULL
55	NULL
Promoter	NULL
Region	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
positive	NULL
regulatory	NULL
region	NULL
in	NULL
the	NULL
be/-2	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Diagram	NULL
of	NULL
the	NULL
bel-2	NULL
5	NULL
'	NULL
sequences	NULL
used	NULL
in	NULL
the	NULL
constructs	NULL
with	NULL
relevant	NULL
restriction	NULL
enzyme	NULL
sites	NULL
indicated	NULL
and	NULL
luciferase	NULL
activity	NULL
of	NULL
progressive	NULL
5	NULL
'	NULL
deletions	NULL
of	NULL
the	NULL
bel-2	NULL
promoter	NULL
region	NULL
in	NULL
DHL-9	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
relative	NULL
to	NULL
the	NULL
luciferase	NULL
activity	NULL
of	NULL
the	NULL
basal	NULL
promoter	NULL
(	NULL
-1526	NULL
)	NULL
construct	NULL
,	NULL
which	NULL
was	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
1	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Diagram	NULL
of	NULL
the	NULL
bel-2	NULL
5	NULL
'	NULL
sequences	NULL
used	NULL
in	NULL
the	NULL
constructs	NULL
and	NULL
results	NULL
of	NULL
transient-transfection	NULL
analysis	NULL
of	NULL
the	NULL
region	NULL
between	NULL
SeclI	NULL
(	NULL
-1640	NULL
)	NULL
and	NULL
BsrFI	NULL
(	NULL
-1526	NULL
)	NULL
.	NULL

studies	NULL
suggest	NULL
that	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
URE	NULL
was	NULL
located	NULL
between	NULL
-1611	NULL
and	NULL
-1591	NULL
.	NULL

Constructs	NULL
with	NULL
deletions	NULL
or	NULL
additions	NULL
of	NULL
sequence	NULL
between	NULL
the	NULL
two	NULL
regions	NULL
that	NULL
disrupted	NULL
the	NULL
helical	NULL
spacing	NULL
resulted	NULL
in	NULL
promoter	NULL
activities	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
DRE	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
disruption	NULL
of	NULL
the	NULL
helical	NULL
spacing	NULL
between	NULL
the	NULL
URE	NULL
and	NULL
DRE	NULL
leads	NULL
to	NULL
loss	NULL
of	NULL
the	NULL
positive	NULL
interaction	NULL
between	NULL
these	NULL
elements	NULL
.	NULL

The	NULL
URE	NULL
has	NULL
not	NULL
been	NULL
further	NULL
characterized	NULL
.	NULL

Sequence	NULL
specificity	NULL
of	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
DRE	NULL
.	NULL

EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
obtained	NULL
from	NULL
the	NULL
B-cell	NULL
lines	NULL
DHL-9	NULL
,	NULL
Ramos	NULL
,	NULL
Nalm-6	NULL
,	NULL
and	NULL
Reh	NULL
with	NULL
an	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
bel-2	NULL
sequence	NULL
-1552	NULL
to	NULL
-1525	NULL
or	NULL
-1552	NULL
to	NULL
-1535	NULL
,	NULL
both	NULL
of	NULL
which	NULL
contain	NULL
WtDRE	NULL
,	NULL
revealed	NULL
four	NULL
specific	NULL
bands	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
INDUCTION	NULL
OF	NULL
be/-2	NULL
BY	NULL
CREB	NULL
PROTEINS	NULL
5549	NULL
Competitor	NULL
:	NULL
0	NULL
â¬	NULL
&	NULL
bCRE	NULL
1-	NULL
Â»	NULL
bCRE	NULL
2	NULL
-i	NULL
Â»	NULL
bCRE	NULL
3	NULL
-	NULL
#	NULL
REO	NULL
-	NULL
Â»	NULL
\nemes	NULL
bCRE	NULL
2	NULL
-a	NULL
creo	NULL
bCRE	NULL
3	NULL
-B	NULL
ous	NULL
bused	NULL
pased	NULL
pored	NULL
CREO	NULL
-i	NULL
``	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
6	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

EMSA	NULL
with	NULL
DRE	NULL
oligonucleotides	NULL
and	NULL
DHL-9	NULL
nuclear	NULL
extracts	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
with	NULL
the	NULL
wild-type	NULL
bCRE	NULL
site	NULL
and	NULL
mutated	NULL
sites	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
different	NULL
DRE	NULL
oligonucleotides	NULL
are	NULL
listed	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
specific	NULL
complexes	NULL
;	NULL
the	NULL
two	NULL
complexes	NULL
that	NULL
migrate	NULL
faster	NULL
than	NULL
the	NULL
CREO	NULL
complex	NULL
are	NULL
nonspecific	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Competition	NULL
with	NULL
mutated	NULL
CRE	NULL
oligonucleotides	NULL
.	NULL

The	NULL
indicated	NULL
oligonucleotide	NULL
is	NULL
present	NULL
at	NULL
a	NULL
50-fold	NULL
molar	NULL
excess	NULL
.	NULL

The	NULL
specific	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

(	NULL
the	NULL
results	NULL
for	NULL
DHL-9	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Sequence	NULL
mutation	NULL
analysis	NULL
within	NULL
the	NULL
DRE	NULL
identified	NULL
two	NULL
distinguishable	NULL
protein-binding	NULL
sites	NULL
by	NULL
EMSA	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
and	NULL
by	NULL
EMSA	NULL
with	NULL
competition	NULL
with	NULL
the	NULL
mutated	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

The	NULL
5	NULL
'	NULL
site	NULL
spanned	NULL
the	NULL
sequence	NULL
from	NULL
-1552	NULL
to	NULL
-1541	NULL
and	NULL
produced	NULL
a	NULL
single	NULL
band	NULL
on	NULL
EMSA	NULL
which	NULL
corresponded	NULL
to	NULL
the	NULL
fastest	NULL
migrating	NULL
of	NULL
the	NULL
four	NULL
specific	NULL
bands	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
3	NULL
'	NULL
site	NULL
spanned	NULL
from	NULL
-1547	NULL
to	NULL
-1534	NULL
and	NULL
produced	NULL
one	NULL
slowly	NULL
migrating	NULL
band	NULL
and	NULL
two	NULL
more	NULL
rapidly	NULL
migrating	NULL
bands	NULL
(	NULL
bands	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
3	NULL
from	NULL
most	NULL
slowly	NULL
to	NULL
most	NULL
rapidly	NULL
migrating	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
3	NULL
'	NULL
site	NULL
contains	NULL
a	NULL
complete	NULL
CRE	NULL
consensus	NULL
sequence	NULL
,	NULL
while	NULL
the	NULL
5	NULL
'	NULL
site	NULL
contains	NULL
only	NULL
part	NULL
of	NULL
the	NULL
CRE	NULL
.	NULL

Consequently	NULL
,	NULL
they	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
bel-2	NULL
CRE	NULL
(	NULL
bCRE	NULL
)	NULL
site	NULL
and	NULL
the	NULL
CRE-overlapping	NULL
site	NULL
(	NULL
CREO	NULL
site	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

EMSA	NULL
with	NULL
the	NULL
CRE	NULL
consensus	NULL
oligonucleotide	NULL
with	NULL
be/-2-flanking	NULL
sequences	NULL
yielded	NULL
the	NULL
same	NULL
four	NULL
complexes	NULL
that	NULL
were	NULL
seen	NULL
with	NULL
the	NULL
WtDRE	NULL
oligonucleotide	NULL
,	NULL
and	NULL
the	NULL
two	NULL
oligonucleotides	NULL
competed	NULL
against	NULL
one	NULL
another	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
CREO	NULL
site	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
homologous	NULL
to	NULL
any	NULL
known	NULL
transcription	NULL
factor	NULL
consensus-binding	NULL
site	NULL
.	NULL

Transient-transfection	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
DHL-9	NULL
cells	NULL
and	NULL
reporter	NULL
gene	NULL
constructs	NULL
that	NULL
contained	NULL
mutations	NULL
in	NULL
the	NULL
CREO	NULL
and	NULL
bCRE	NULL
sites	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
URE	NULL
site	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
it	NULL
appeared	NULL
the	NULL
bCRE	NULL
site	NULL
was	NULL
responsible	NULL
for	NULL
most	NULL
if	NULL
not	NULL
all	NULL
of	NULL
the	NULL
positive	NULL
regulatory	NULL
activity	NULL
in	NULL
this	NULL
area	NULL
.	NULL

The	NULL
CREO	NULL
site	NULL
appeared	NULL
to	NULL
have	NULL
only	NULL
weak	NULL
stimulatory	NULL
activity	NULL
.	NULL

The	NULL
5'-	NULL
and	NULL
3'-binding	NULL
sites	NULL
were	NULL
also	NULL
distinguishable	NULL
by	NULL
in	NULL
vitro	NULL
methylation	NULL
interference	NULL
(	NULL
footprinting	NULL
)	NULL
analysis	NULL
,	NULL
which	NULL
confirmed	NULL
the	NULL
site	NULL
lengths	NULL
of	NULL
-1552	NULL
to	NULL
-1541	NULL
and	NULL
-1547	NULL
to	NULL
-1534	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Protein	NULL
binding	NULL
to	NULL
the	NULL
bCRE	NULL
was	NULL
strongly	NULL
inhibited	NULL
(	NULL
>	NULL
60	NULL
%	NULL
inhibition	NULL
)	NULL
by	NULL
guanine	NULL
methylation	NULL
at	NULL
sites	NULL
-1545	NULL
,	NULL
-1543	NULL
,	NULL
-1541	NULL
,	NULL
and	NULL
-1540	NULL
.	NULL

Weaker	NULL
inhibition	NULL
(	NULL
35	NULL
to	NULL
60	NULL
%	NULL
inhibition	NULL
)	NULL
was	NULL
seen	NULL
at	NULL
sites	NULL
-1547	NULL
and	NULL
-1535	NULL
.	NULL

Protein	NULL
binding	NULL
to	NULL
the	NULL
CREO	NULL
site	NULL
was	NULL
strongly	NULL
inhibited	NULL
by	NULL
methylation	NULL
at	NULL
sites	NULL
-1549	NULL
,	NULL
-1548	NULL
,	NULL
-1547	NULL
,	NULL
and	NULL
-1545	NULL
.	NULL

Weaker	NULL
inhibition	NULL
was	NULL
seen	NULL
at	NULL
sites	NULL
-1552	NULL
and	NULL
-1543	NULL
.	NULL

This	NULL
analysis	NULL
confirmed	NULL
an	NULL
overlap	NULL
between	NULL
the	NULL
bCRE	NULL
and	NULL
the	NULL
CREO	NULL
sites	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
bCRE-binding	NULL
proteins	NULL
.	NULL

To	NULL
further	NULL
study	NULL
the	NULL
proteins	NULL
interacting	NULL
with	NULL
the	NULL
bCRE	NULL
site	NULL
,	NULL
UV	NULL
crosslinking	NULL
and	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
of	NULL
the	NULL
three	NULL
upper	NULL
bands	NULL
obtained	NULL
by	NULL
EMSA	NULL
with	NULL
the	NULL
mC1,4	NULL
oligo-	NULL
TABLE	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
DRE	NULL
on	NULL
protein	NULL
binding	NULL
by	NULL
EMSA	NULL
and	NULL
on	NULL
transcriptional	NULL
activity	NULL
measured	NULL
by	NULL
transient	NULL
transfections	NULL
with	NULL
promoter-luciferase	NULL
constructs	NULL
in	NULL
DHL-9	NULL
cells	NULL
EMSA	NULL
binding	NULL
.	NULL

Construct	NULL
``	NULL
Sequence	NULL
of	NULL
the	NULL
DRE	NULL
site	NULL
``	NULL
CRFO	NULL
bCRE	NULL
Lzzgggs	NULL
Â©	NULL
band	NULL
bands	NULL
WtURE/DRE	NULL
GAACCGTGTGACGTTACGCA	NULL
+++	NULL
+++	NULL
3.07	NULL
+	NULL
0.48	NULL
MutCRE	NULL
GAACCGTGTGAATTTACGCA	NULL
+	NULL
-	NULL
1.34	NULL
+	NULL
0.26	NULL
WtURE	NULL
GAACCGTGTACTAGTGGACA	NULL
+	NULL
-	NULL
0.52	NULL
+	NULL
0.14	NULL
WtDRE	NULL
GAACCGTGTGACGTTACGCA	NULL
+++	NULL
+++	NULL
1.51	NULL
+	NULL
0.24	NULL
mC2-3	NULL
GCCGCGTGTeaAceTTACGCA	NULL
+	NULL
+++	NULL
1.45	NULL
+	NULL
0.18	NULL
mCl,4	NULL
TAACAGTGTGACGTTACGCA	NULL
+	NULL
+++	NULL
1.58	NULL
+	NULL
0.30	NULL
mC6,8	NULL
GAACCTTETGACGTTACGCA	NULL
+	NULL
+	NULL
1.14	NULL
+	NULL
0.19	NULL
mC12,13	NULL
GAACCGTGTGAATTTACGCA	NULL
+	NULL
-	NULL
0.98	NULL
+	NULL
0.12	NULL
mC13,14	NULL
GAACCGTGTGACTATACGCA	NULL
+++	NULL
-	NULL
1.17	NULL
+	NULL
0.14	NULL
mC13-17	NULL
GAACCGTGTGACTAGTGGCA	NULL
+++	NULL
-	NULL
1.13	NULL
+	NULL
0.18	NULL
Basal	NULL
bel-2	NULL
promoter	NULL
control	NULL
construct	NULL
1.00	NULL
+	NULL
0.11	NULL
``	NULL
A	NULL
schematic	NULL
representation	NULL
of	NULL
the	NULL
expression	NULL
vectors	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
.	NULL

*	NULL
Boldface	NULL
type	NULL
highlights	NULL
the	NULL
CRE	NULL
consensus	NULL
sequence	NULL
.	NULL

Underlined	NULL
nucleotides	NULL
represent	NULL
mutations	NULL
from	NULL
the	NULL
wild-type	NULL
sequence	NULL
.	NULL

5550	NULL
WILSON	NULL
ET	NULL
AL	NULL
.	NULL

F	NULL
2+3	NULL
1	NULL
F	NULL
2+3	NULL
1	NULL
grr	NULL
T	NULL
?	NULL

A	NULL
Â§	NULL
&	NULL
C	NULL
T	NULL
*	NULL
*	NULL
A	NULL
T	NULL
#	NULL
G	NULL
e	NULL
s	NULL
%	NULL
T	NULL
C	NULL
Â¥	NULL
Ge	NULL
A	NULL
#	NULL
Â®	NULL
C	NULL
o	NULL
~-	NULL
A	NULL
T	NULL
Â®	NULL
#	NULL
=	NULL
@	NULL
~1535	NULL
7	NULL
0G	NULL
-1552	NULL
Coding	NULL
Noncoding	NULL
F	NULL
Creo	NULL
F	NULL
Creo	NULL
7~	NULL
A	NULL
'	NULL
'	NULL
c	NULL
oG	NULL
&	NULL
/	NULL
T	NULL
T	NULL
s	NULL
7	NULL
#	NULL
G	NULL
#	NULL
G=	NULL
T	NULL
#	NULL
G=	NULL
aG	NULL
C	NULL
C	NULL
A	NULL
C	NULL
*~	NULL
g	NULL
A	NULL
A	NULL
d-	NULL
``	NULL
~1556	NULL
-1541	NULL
Coding	NULL
Noncoding	NULL
o	NULL
@	NULL
oa	NULL
o	NULL
FAACCETCETCEACCETTACE	NULL
1552	NULL
Â°	NULL
+1535	NULL
CTTGGCACACTQCAATGC	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Methylation	NULL
interference	NULL
analysis	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
formed	NULL
with	NULL
DHL-9	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
DRE	NULL
oligonucleotides	NULL
.	NULL

The	NULL
EMSA	NULL
complexes	NULL
analyzed	NULL
are	NULL
indicated	NULL
above	NULL
cach	NULL
lane	NULL
.	NULL

bCRE	NULL
EMSA	NULL
complexes	NULL
1	NULL
through	NULL
3	NULL
,	NULL
formed	NULL
with	NULL
the	NULL
WHDRE	NULL
oligonucleotide	NULL
,	NULL
are	NULL
shown	NULL
above	NULL
the	NULL
CREO	NULL
EMSA	NULL
complexes	NULL
formed	NULL
with	NULL
the	NULL
bCREO	NULL
oligonucleotide	NULL
.	NULL

The	NULL
guanine	NULL
residues	NULL
that	NULL
showed	NULL
strong	NULL
protection	NULL
are	NULL
indicated	NULL
by	NULL
solid	NULL
circles	NULL
(	NULL
CRE	NULL
)	NULL
or	NULL
squares	NULL
(	NULL
CREO	NULL
)	NULL
;	NULL
those	NULL
that	NULL
showed	NULL
weaker	NULL
protection	NULL
are	NULL
indicated	NULL
by	NULL
open	NULL
circles	NULL
(	NULL
CRE	NULL
)	NULL
or	NULL
squares	NULL
(	NULL
CREO	NULL
)	NULL
.	NULL

The	NULL
CRE	NULL
site	NULL
is	NULL
underlined	NULL
.	NULL

The	NULL
protected	NULL
guanine	NULL
residues	NULL
are	NULL
summarized	NULL
in	NULL
the	NULL
sequence	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
figure	NULL
,	NULL
and	NULL
the	NULL
bCRE	NULL
site	NULL
is	NULL
indicated	NULL
in	NULL
boldface	NULL
letters	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

nucleotide	NULL
were	NULL
performed	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

The	NULL
fourth	NULL
band	NULL
obtained	NULL
with	NULL
this	NULL
probe	NULL
corresponded	NULL
to	NULL
the	NULL
CREO	NULL
site	NULL
complex	NULL
and	NULL
was	NULL
not	NULL
studied	NULL
.	NULL

UV	NULL
cross-linking	NULL
of	NULL
the	NULL
most	NULL
slowly	NULL
migrating	NULL
bCRE	NULL
band	NULL
,	NULL
band	NULL
1	NULL
,	NULL
obtained	NULL
by	NULL
EMSA	NULL
with	NULL
mC1,4	NULL
yielded	NULL
two	NULL
protein-DNA	NULL
complexes	NULL
migrating	NULL
at	NULL
77	NULL
and	NULL
88	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Correcting	NULL
for	NULL
oligonucleotide	NULL
size	NULL
,	NULL
proteins	NULL
of	NULL
approximately	NULL
63	NULL
and	NULL
67	NULL
kDa	NULL
were	NULL
predicted	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
this	NULL
EMSA	NULL
band	NULL
yielded	NULL
two	NULL
faintly	NULL
labeled	NULL
protein-DNA	NULL
complexes	NULL
migrating	NULL
at	NULL
130	NULL
and	NULL
170	NULL
kDa	NULL
,	NULL
which	NULL
may	NULL
represent	NULL
dimeric	NULL
forms	NULL
of	NULL
the	NULL
faster-migrating	NULL
proteins	NULL
.	NULL

UV	NULL
cross-linking	NULL
of	NULL
bCRE	NULL
band	NULL
2	NULL
revealed	NULL
a	NULL
protein-DNA	NULL
complex	NULL
of	NULL
53	NULL
kDa	NULL
(	NULL
corrected	NULL
protein	NULL
size	NULL
,	NULL
43	NULL
kDa	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

A	NULL
faintly	NULL
labeled	NULL
protein-DNA	NULL
complex	NULL
of	NULL
approximately	NULL
100	NULL
kDa	NULL
,	NULL
which	NULL
may	NULL
represent	NULL
a	NULL
homodimeric	NULL
complex	NULL
of	NULL
the	NULL
43-kDa	NULL
protein	NULL
,	NULL
was	NULL
seen	NULL
.	NULL

The	NULL
fastest	NULL
migrating	NULL
bCRE	NULL
band	NULL
,	NULL
band	NULL
3	NULL
,	NULL
yielded	NULL
two	NULL
protein-DNA	NULL
complexes	NULL
of	NULL
45	NULL
and	NULL
53	NULL
kDa	NULL
(	NULL
corrected	NULL
protein	NULL
sizes	NULL
,	NULL
34	NULL
and	NULL
43	NULL
kDa	NULL
,	NULL
respectively	NULL
)	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
a	NULL
faintly	NULL
labeled	NULL
protein-DNA	NULL
complex	NULL
of	NULL
approximately	NULL
94	NULL
kDa	NULL
was	NULL
seen	NULL
,	NULL
which	NULL
may	NULL
represent	NULL
a	NULL
het-erodimeric	NULL
complex	NULL
.	NULL

EMSA	NULL
supershift	NULL
analyses	NULL
of	NULL
the	NULL
bCRE	NULL
complexes	NULL
were	NULL
performed	NULL
with	NULL
antibodies	NULL
directed	NULL
against	NULL
several	NULL
known	NULL
CREBs	NULL
(	NULL
ATF-1	NULL
,	NULL
ATF-2	NULL
,	NULL
ATF-3	NULL
,	NULL
CREB	NULL
,	NULL
CREB-2	NULL
,	NULL
and	NULL
CREM-1	NULL
)	NULL
and	NULL
several	NULL
non-CREBs	NULL
(	NULL
PEA3	NULL
,	NULL
c-jun/AP-1	NULL
,	NULL
c-fos	NULL
,	NULL
egr-1	NULL
,	NULL
and	NULL
ets1/ets2	NULL
)	NULL
.	NULL

Performing	NULL
this	NULL
analysis	NULL
with	NULL
the	NULL
mC1,4	NULL
oligonucleotide	NULL
probe	NULL
demonstrated	NULL
a	NULL
supershift	NULL
of	NULL
bCRE	NULL
band	NULL
1	NULL
with	NULL
antibodies	NULL
against	NULL
ATF-2	NULL
and	NULL
ATF-1/ATF-2	NULL
.	NULL

bCRE	NULL
band	NULL
2	NULL
was	NULL
supershifted	NULL
with	NULL
antibodies	NULL
against	NULL
CREB	NULL
and	NULL
ATF-1/CREB	NULL
,	NULL
and	NULL
bCRE	NULL
band	NULL
3	NULL
was	NULL
supershifted	NULL
only	NULL
with	NULL
antibody	NULL
against	NULL
ATF-1/CREB	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

None	NULL
of	NULL
the	NULL
other	NULL
antibodies	NULL
tested	NULL
shifted	NULL
either	NULL
the	NULL
bCRE	NULL
bands	NULL
or	NULL
the	NULL
CREO	NULL
band	NULL
.	NULL

Western	NULL
blot	NULL
(	NULL
immunoblot	NULL
)	NULL
analysis	NULL
of	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
revealed	NULL
abundant	NULL
expression	NULL
of	NULL
ATF-2	NULL
(	NULL
reactive	NULL
antigens	NULL
found	NULL
at	NULL
62	NULL
,	NULL
67	NULL
,	NULL
and	NULL
170	NULL
kDa	NULL
)	NULL
and	NULL
CREB	NULL
(	NULL
reactive	NULL
antigen	NULL
found	NULL
at	NULL
43	NULL
kDa	NULL
[	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

By	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
the	NULL
ATF-1/ATF-2	NULL
antibody	NULL
displayed	NULL
weak	NULL
cross-reactivity	NULL
with	NULL
the	NULL
ATF-2	NULL
antigens	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
supershift	NULL
A	NULL
B	NULL
a	NULL
l	NULL
LL	NULL
CC	NULL
o	NULL
<	NULL
q	NULL
o	NULL
ou	NULL
E	NULL
it	NULL
.	NULL

E	NULL
Â¥	NULL
Â¢	NULL
E	NULL
E	NULL
2	NULL
a	NULL
Â¥	NULL
LL	NULL
LL	NULL
LL	NULL
i-	NULL
CC	NULL
CC	NULL
Co	NULL
w	NULL
2	NULL
E	NULL
E	NULL
E	NULL
<	NULL
&	NULL
9	NULL
4	NULL
4	NULL
9	NULL
Â§	NULL
4	NULL
9p	NULL
9	NULL
9	NULL
9	NULL
s	NULL
&	NULL
a	NULL
$	NULL
0	NULL
&	NULL
&	NULL
80	NULL
as	NULL
s	NULL
-	NULL
200	NULL
kDa	NULL
Supershift	NULL
1	NULL
Z	NULL
:	NULL
-	NULL
97	NULL
kDa	NULL
_-	NULL
69	NULL
kDa	NULL
Supershlft2,3	NULL
:	NULL
=*	NULL
e	NULL
bCRE	NULL
1	NULL
Heel	NULL
aut	NULL
w	NULL
-	NULL
46	NULL
kDa	NULL
bCRE	NULL
2	NULL
-	NULL
#	NULL
bCRE	NULL
3	NULL
-a	NULL
CREO-=Â®	NULL
Rs	NULL
b	NULL
JV	NULL
tml	NULL
kame	NULL
pos	NULL
gree	NULL
posed	NULL
mund	NULL
v	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
bCRE	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Denaturing	NULL
SDS-polyacrylamide	NULL
gel	NULL
analysis	NULL
of	NULL
the	NULL
UV	NULL
cross-linked	NULL
EMSA	NULL
complexes	NULL
formed	NULL
with	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
and	NULL
the	NULL
mC1,4	NULL
oligonucleotide	NULL
.	NULL

The	NULL
EMSA	NULL
complexes	NULL
analyzed	NULL
are	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

The	NULL
migration	NULL
of	NULL
the	NULL
molecular	NULL
mass	NULL
markers	NULL
is	NULL
shown	NULL
on	NULL
the	NULL
right	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
supershift	NULL
analysis	NULL
of	NULL
the	NULL
complexes	NULL
formed	NULL
with	NULL
the	NULL
DRE	NULL
oligonucleotide	NULL
and	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
complexes	NULL
and	NULL
the	NULL
corresponding	NULL
supershifted	NULL
complexes	NULL
.	NULL

Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
2	NULL
ug/ul	NULL
DHL-9	NULL
Nuclear	NULL
Protein	NULL
Added	NULL
Â©	NULL
a	NULL
2	NULL
zo	NULL
g	NULL
e	NULL
#	NULL
conc	NULL
â	NULL
rerr	NULL
'	NULL
i't'rjgï¬ï¬ï¬grgwï¬	NULL
2	NULL
Â§	NULL
7	NULL
Â§	NULL
S3	NULL
2	NULL
2	NULL
f	NULL
bCRE	NULL
1	NULL
pm	NULL
+	NULL
â	NULL
bere	NULL
2	NULL
*	NULL
e	NULL
-	NULL
Â§	NULL
R	NULL
*	NULL
IM	NULL
Trunccï¬lgg-p	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Interaction	NULL
of	NULL
a	NULL
purified	NULL
truncated	NULL
CREB	NULL
with	NULL
the	NULL
CREBs	NULL
in	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
by	NULL
EMSA	NULL
with	NULL
the	NULL
mC1,4	NULL
oligonucleotide	NULL
.	NULL

Decreasing	NULL
amounts	NULL
of	NULL
a	NULL
purified	NULL
truncated	NULL
CREB	NULL
were	NULL
added	NULL
to	NULL
a	NULL
constant	NULL
protein	NULL
concentration	NULL
from	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
(	NULL
2	NULL
pug/pl	NULL
)	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
complexes	NULL
formed	NULL
with	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
,	NULL
the	NULL
complex	NULL
formed	NULL
by	NULL
the	NULL
truncated	NULL
CREB	NULL
protein	NULL
,	NULL
and	NULL
the	NULL
complex	NULL
of	NULL
intermediate	NULL
mobility	NULL
formed	NULL
with	NULL
the	NULL
truncated	NULL
CREB	NULL
and	NULL
with	NULL
CREB	NULL
in	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
.	NULL

Quantitation	NULL
of	NULL
the	NULL
bands	NULL
was	NULL
performed	NULL
for	NULL
the	NULL
EMSA	NULL
with	NULL
1.0	NULL
and	NULL
5.0	NULL
ng	NULL
of	NULL
truncated	NULL
CREB	NULL
per	NULL
ml	NULL
.	NULL

There	NULL
was	NULL
no	NULL
change	NULL
in	NULL
the	NULL
relative	NULL
intensity	NULL
of	NULL
the	NULL
bCRE1	NULL
and	NULL
CREO	NULL
bands	NULL
.	NULL

With	NULL
1.0	NULL
and	NULL
5.0	NULL
ng	NULL
of	NULL
truncated	NULL
CREB	NULL
per	NULL
pl	NULL
,	NULL
CRE	NULL
band	NULL
2	NULL
decreased	NULL
by	NULL
18	NULL
and	NULL
70	NULL
%	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
bCRE	NULL
band	NULL
3	NULL
decreased	NULL
by	NULL
28	NULL
and	NULL
83	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

activity	NULL
seen	NULL
with	NULL
this	NULL
antibody	NULL
was	NULL
a	NULL
result	NULL
of	NULL
cross-reactivity	NULL
with	NULL
ATF-2	NULL
and	NULL
not	NULL
involvement	NULL
of	NULL
ATF-1	NULL
in	NULL
the	NULL
protein-DNA	NULL
complex	NULL
bCRE	NULL
band	NULL
1	NULL
.	NULL

The	NULL
ATF-1/CREB	NULL
antibody	NULL
is	NULL
known	NULL
to	NULL
have	NULL
polyspecific	NULL
reactivity	NULL
.	NULL

By	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
it	NULL
was	NULL
strongly	NULL
reactive	NULL
with	NULL
CREB-1	NULL
and	NULL
weakly	NULL
reactive	NULL
with	NULL
several	NULL
other	NULL
antigens	NULL
(	NULL
of	NULL
35	NULL
,	NULL
38	NULL
,	NULL
49	NULL
,	NULL
65	NULL
,	NULL
74	NULL
,	NULL
and	NULL
138	NULL
kDa	NULL
)	NULL
.	NULL

Members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
form	NULL
homo-	NULL
and	NULL
heterodimers	NULL
.	NULL

To	NULL
further	NULL
confirm	NULL
the	NULL
involvement	NULL
of	NULL
CREB/ATF	NULL
family	NULL
members	NULL
in	NULL
the	NULL
bCRE	NULL
complexes	NULL
,	NULL
EMSA	NULL
of	NULL
the	NULL
mC1,4	NULL
oligonucleotide	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
decreasing	NULL
amounts	NULL
of	NULL
a	NULL
truncated	NULL
CREB	NULL
that	NULL
contains	NULL
the	NULL
DNA-binding	NULL
and	NULL
dimerization	NULL
domains	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

High	NULL
concentrations	NULL
of	NULL
this	NULL
protein	NULL
(	NULL
>	NULL
10	NULL
ng/pul	NULL
)	NULL
effectively	NULL
blocked	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
extract	NULL
proteins	NULL
to	NULL
both	NULL
the	NULL
bCRE	NULL
and	NULL
CREO	NULL
sites	NULL
,	NULL
confirming	NULL
that	NULL
these	NULL
sites	NULL
overlap	NULL
and	NULL
that	NULL
the	NULL
bCRE	NULL
site	NULL
can	NULL
function	NULL
as	NULL
a	NULL
CRE	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Lower	NULL
concentrations	NULL
(	NULL
0.008	NULL
to	NULL
5	NULL
ng/pul	NULL
)	NULL
of	NULL
the	NULL
truncated	NULL
CREB	NULL
produced	NULL
one	NULL
intermediate	NULL
migrating	NULL
band	NULL
with	NULL
concurrent	NULL
relative	NULL
diminution	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
bCRE	NULL
band	NULL
2	NULL
and	NULL
3	NULL
but	NULL
not	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
bCRE	NULL
band	NULL
1	NULL
or	NULL
of	NULL
the	NULL
CREO	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

These	NULL
results	NULL
confirmed	NULL
that	NULL
the	NULL
proteins	NULL
involved	NULL
in	NULL
bCRE	NULL
bands	NULL
2	NULL
and	NULL
3	NULL
are	NULL
capable	NULL
of	NULL
dimerization	NULL
with	NULL
CREB	NULL
.	NULL

As	NULL
ATF-2	NULL
is	NULL
a	NULL
distant	NULL
relative	NULL
of	NULL
CREB	NULL
and	NULL
has	NULL
not	NULL
been	NULL
shown	NULL
to	NULL
dimerize	NULL
with	NULL
CREB	NULL
,	NULL
it	NULL
is	NULL
not	NULL
surprising	NULL
that	NULL
no	NULL
interaction	NULL
between	NULL
the	NULL
truncated	NULL
CREB	NULL
and	NULL
the	NULL
bCRE	NULL
band	NULL
1	NULL
was	NULL
seen	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
be/-2	NULL
CRE	NULL
site	NULL
appears	NULL
to	NULL
be	NULL
able	NULL
to	NULL
form	NULL
three	NULL
complexes	NULL
with	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
,	NULL
each	NULL
represented	NULL
by	NULL
a	NULL
specific	NULL
EMSA	NULL
band	NULL
.	NULL

The	NULL
most	NULL
slowly	NULL
migrating	NULL
complex	NULL
(	NULL
bCRE	NULL
band	NULL
1	NULL
)	NULL
appears	NULL
to	NULL
consist	NULL
of	NULL
dimerized	NULL
63-	NULL
and	NULL
67-kDa	NULL
forms	NULL
of	NULL
ATF-2	NULL
.	NULL

The	NULL
middle	NULL
complex	NULL
(	NULL
bCRE	NULL
band	NULL
2	NULL
)	NULL
is	NULL
apparently	NULL
a	NULL
homodimer	NULL
of	NULL
CREB	NULL
,	NULL
and	NULL
the	NULL
fastest-migrating	NULL
complex	NULL
(	NULL
bCRE	NULL
band	NULL
3	NULL
)	NULL
is	NULL
a	NULL
heterodimer	NULL
of	NULL
CREB	NULL
and	NULL
possibly	NULL
ATF-1	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
full-length	NULL
bel-2	NULL
promoter	NULL
,	NULL
site-directed	NULL
mutagenesis	NULL
was	NULL
used	NULL
to	NULL
create	NULL
a	NULL
2-bp	NULL
change	NULL
in	NULL
the	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
WtURE/DRE	NULL
construct	NULL
(	NULL
MutCRE	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
the	NULL
promoter	NULL
activity	NULL
decreased	NULL
by	NULL
83	NULL
%	NULL
relative	NULL
to	NULL
the	NULL
WtURE/DRE	NULL
construct	NULL
.	NULL

Induction	NULL
of	NULL
be/-2	NULL
promoter	NULL
activity	NULL
during	NULL
B-cell	NULL
activation	NULL
and	NULL
rescue	NULL
from	NULL
apoptosis	NULL
.	NULL

Because	NULL
the	NULL
CRE	NULL
is	NULL
an	NULL
inducible	NULL
INDUCTION	NULL
OF	NULL
be/-2	NULL
BY	NULL
CREB	NULL
PROTEINS	NULL
5551	NULL
moe	NULL
oto	NULL
0	NULL
a	NULL
o	NULL
d	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
o	NULL
a	NULL
a	NULL
&	NULL
in	NULL
&	NULL
in	NULL
Basal	NULL
-	NULL
WtUNE/DRE	NULL
MutCRE	NULL
Promoter	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
mutation	NULL
of	NULL
the	NULL
bel-2	NULL
CRE	NULL
site	NULL
on	NULL
promoter	NULL
activity	NULL
in	NULL
DHL-9	NULL
cells	NULL
.	NULL

Luciferase	NULL
activities	NULL
of	NULL
the	NULL
WtURE/DRE	NULL
and	NULL
the	NULL
construct	NULL
with	NULL
the	NULL
mutated	NULL
CRE	NULL
site	NULL
(	NULL
MutCRE	NULL
)	NULL
are	NULL
shown	NULL
relative	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
basal	NULL
promoter	NULL
.	NULL

regulatory	NULL
element	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
a	NULL
CREB	NULL
was	NULL
involved	NULL
in	NULL
the	NULL
increase	NULL
in	NULL
be/-2	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
.	NULL

DHL-9	NULL
cells	NULL
could	NULL
not	NULL
be	NULL
used	NULL
for	NULL
these	NULL
studies	NULL
because	NULL
they	NULL
do	NULL
not	NULL
express	NULL
surface	NULL
IgM	NULL
.	NULL

The	NULL
murine	NULL
B-cell	NULL
line	NULL
,	NULL
BAL-17	NULL
,	NULL
was	NULL
chosen	NULL
because	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
recapitulate	NULL
many	NULL
of	NULL
the	NULL
characteristics	NULL
of	NULL
primary	NULL
B	NULL
cells	NULL
after	NULL
surface	NULL
Ig	NULL
receptor	NULL
cross-linking	NULL
.	NULL

Although	NULL
BAL-17	NULL
cells	NULL
express	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
be/-2	NULL
,	NULL
cross-linking	NULL
of	NULL
the	NULL
surface	NULL
Ig	NULL
receptor	NULL
or	NULL
treatment	NULL
with	NULL
PMA	NULL
leads	NULL
to	NULL
a	NULL
further	NULL
2.5-	NULL
to	NULL
3.5-fold	NULL
increase	NULL
in	NULL
be/-2	NULL
mRNA	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
effect	NULL
on	NULL
be/-2	NULL
promoter	NULL
activity	NULL
,	NULL
cross-linking	NULL
of	NULL
surface	NULL
Ig	NULL
receptor	NULL
was	NULL
performed	NULL
with	NULL
goat	NULL
anti-IgM	NULL
antibodies	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
be/-2-luciferase	NULL
constructs	NULL
.	NULL

The	NULL
be/-2	NULL
promoter	NULL
constructs	NULL
used	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
bel-2	NULL
promoter	NULL
increased	NULL
by	NULL
threefold	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
.	NULL

We	NULL
used	NULL
either	NULL
dibutyryl-cAMP	NULL
or	NULL
forskolin	NULL
to	NULL
increase	NULL
cAMP	NULL
levels	NULL
.	NULL

This	NULL
PKA	NULL
pathway	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
CREBs	NULL
in	NULL
many	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7C	NULL
,	NULL
forskolin	NULL
did	NULL
not	NULL
produce	NULL
an	NULL
increase	NULL
in	NULL
be/-2	NULL
promoter	NULL
activity	NULL
.	NULL

Similar	NULL
negative	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
dibutyryl-cAMP	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Because	NULL
CREB	NULL
is	NULL
phosphorylated	NULL
by	NULL
other	NULL
kinases	NULL
,	NULL
including	NULL
PKC	NULL
,	NULL
we	NULL
treated	NULL
the	NULL
BAL-17	NULL
cells	NULL
with	NULL
PMA	NULL
.	NULL

PMA	NULL
produced	NULL
a	NULL
threefold	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
.	NULL

The	NULL
increase	NULL
in	NULL
activity	NULL
due	NULL
to	NULL
PMA	NULL
was	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
surface	NULL
Ig	NULL
receptor	NULL
cross-linking	NULL
.	NULL

Simultaneous	NULL
stimulation	NULL
with	NULL
PMA	NULL
and	NULL
Ig	NULL
cross-linking	NULL
resulted	NULL
in	NULL
little	NULL
additional	NULL
stimulation	NULL
of	NULL
promoter	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
stimulation	NULL
evoked	NULL
by	NULL
surface	NULL
Ig	NULL
cross-linking	NULL
was	NULL
almost	NULL
entirely	NULL
due	NULL
to	NULL
a	NULL
PKC	NULL
mechanism	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
a	NULL
control	NULL
plasmid	NULL
(	NULL
Bg/II	NULL
CAT	NULL
)	NULL
that	NULL
contains	NULL
the	NULL
somatostatin	NULL
gene	NULL
promoter	NULL
CRE	NULL
site	NULL
.	NULL

Treatment	NULL
of	NULL
BAL-17	NULL
cells	NULL
with	NULL
PMA	NULL
led	NULL
to	NULL
a	NULL
threefold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
,	NULL
while	NULL
treatment	NULL
with	NULL
forskolin	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
the	NULL
failure	NULL
of	NULL
increased	NULL
cAMP	NULL
levels	NULL
to	NULL
activate	NULL
a	NULL
CRE	NULL
site	NULL
in	NULL
these	NULL
cells	NULL
is	NULL
unclear	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
an	NULL
inhibitor	NULL
of	NULL
PKA	NULL
is	NULL
present	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
we	NULL
used	NULL
for	NULL
these	NULL
studies	NULL
.	NULL

The	NULL
increase	NULL
in	NULL
activity	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
with	NULL
both	NULL
anti-IgM	NULL
and	NULL
PMA	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
CRE	NULL
site	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7C	NULL
,	NULL
there	NULL
was	NULL
no	NULL
change	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
either	NULL
the	NULL
WtURE	NULL
or	NULL
MutCRE	NULL
constructs	NULL
.	NULL

A	NULL
promoter	NULL
construct	NULL
with	NULL
the	NULL
URE	NULL
deleted	NULL
showed	NULL
only	NULL
a	NULL
60	NULL
%	NULL
increase	NULL
in	NULL
activity	NULL
with	NULL
PMA	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
bCRE	NULL
site	NULL
is	NULL
required	NULL
for	NULL
the	NULL
increased	NULL
promoter	NULL
activity	NULL
and	NULL
that	NULL
interaction	NULL
of	NULL
the	NULL
URE	NULL
and	NULL
bCRE	NULL
results	NULL
in	NULL
maximal	NULL
stimulation	NULL
of	NULL
promoter	NULL
activity	NULL
.	NULL

Thus	NULL
,	NULL
be/-2	NULL
expression	NULL
is	NULL
activated	NULL
by	NULL
surface	NULL
Ig	NULL
receptor	NULL
cross-linking	NULL
or	NULL
by	NULL
PMA	NULL
through	NULL
the	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
5'-flanking	NULL
sequence	NULL
.	NULL

5552	NULL
WILSON	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
Basal	NULL
Promoter	NULL
Basal	NULL
Promoter	NULL
Control	NULL
wiure/iore	NULL
[	NULL
_	NULL
ure	NULL
DRE	NULL
|	NULL
Basal	NULL
Promoter	NULL
]	NULL
WtURE	NULL
|__	NULL
URE	NULL
___	NULL
|	NULL
--	NULL
-|	NULL
Basal	NULL
Promoter	NULL
]	NULL
WiDRE	NULL
|	NULL
DRE	NULL
|	NULL
Basal	NULL
Promoter	NULL
]	NULL
MutCRE	NULL
[	NULL
_	NULL
URE	NULL
Mut	NULL
_|	NULL
Basal	NULL
Promoter	NULL
]	NULL
mC	NULL
series	NULL
3.5	NULL
|-z	NULL
$	NULL
|	NULL
&	NULL
so	NULL
al	NULL
Kel	NULL
Â§	NULL
2s	NULL
}	NULL
ts	NULL
)	NULL
3	NULL
E	NULL
20	NULL
}	NULL
in	NULL
ke	NULL
8	NULL
15	NULL
)	NULL
1.0	NULL
is	NULL
Control	NULL
WtURE/DRE	NULL
WtDRE	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

$	NULL
D	NULL
e	NULL
?	NULL

â	NULL
Â®	NULL
Wp	NULL
3	NULL
``	NULL
&	NULL
&	NULL
Â°	NULL
Q	NULL
â	NULL
\X~Â°Â°	NULL
Antibody	NULL
:	NULL
0	NULL
_	NULL
0	NULL
Po	NULL
o	NULL
P	NULL
C	NULL
@	NULL
igM	NULL
:	NULL
-	NULL
=	NULL
-	NULL
-	NULL
-	NULL
+	NULL
+	NULL
Â«	NULL
ae	NULL
emm	NULL
Â«	NULL
-	NULL
PMA	NULL
:	NULL
4+	NULL
0	NULL
-	NULL
-	NULL
040	NULL
-	NULL
-	NULL
+	NULL
Supershift	NULL
--	NULL
bosd	NULL
(	NULL
PW	NULL
p-	NULL
i	NULL
flp	NULL
se	NULL
mae	NULL
et	NULL
a-	NULL
(	NULL
}	NULL
-2	NULL
)	NULL
/	NULL
2	NULL
3	NULL
4	NULL
1	NULL
C	NULL
b	NULL
bn	NULL
s	NULL
b	NULL
6	NULL
...	NULL
N60	NULL
Grund	NULL
2	NULL
3	NULL
Hues	NULL
5	NULL
7	NULL
1	NULL
4	NULL
6	NULL
WtURE	NULL
_	NULL
MutCRE	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
B-cell	NULL
stimuli	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
be/-2	NULL
promoter	NULL
in	NULL
BAL-17	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Diagram	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
constructs	NULL
used	NULL
for	NULL
transient-transfection	NULL
analysis	NULL
.	NULL

(	NULL
B	NULL
)	NULL
S1	NULL
analysis	NULL
of	NULL
be/-2	NULL
mRNA	NULL
levels	NULL
in	NULL
BAL-17	NULL
cells	NULL
after	NULL
treatment	NULL
with	NULL
anti-IgM	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
no	NULL
addition	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
is	NULL
tRNA	NULL
only	NULL
.	NULL

Protected	NULL
fragments	NULL
of	NULL
600	NULL
(	NULL
be/-2	NULL
)	NULL
and	NULL
202	NULL
(	NULL
B	NULL
,	NULL
-microglobulin	NULL
promoter	NULL
region	NULL
(	NULL
Control	NULL
)	NULL
,	NULL
the	NULL
WtURE/DRE	NULL
,	NULL
WtDRE	NULL
,	NULL
WtURE	NULL
,	NULL
and	NULL
MutCRE	NULL
[	NULL
B-2M	NULL
]	NULL
)	NULL
nucleotides	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Transient-transfection	NULL
analysis	NULL
of	NULL
the	NULL
be/-2	NULL
basal	NULL
constructs	NULL
after	NULL
treatment	NULL
of	NULL
BAL-17	NULL
cells	NULL
with	NULL
60	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
,	NULL
4	NULL
pg	NULL
of	NULL
anti-IgM	NULL
per	NULL
ml	NULL
,	NULL
10	NULL
M	NULL
forskolin	NULL
,	NULL
60	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
10	NULL
M	NULL
forskolin	NULL
,	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
anti-IgM	NULL
per	NULL
ml	NULL
plus	NULL
10	NULL
M	NULL
forskolin	NULL
for	NULL
18	NULL
h.	NULL
(	NULL
D	NULL
)	NULL
EMSA	NULL
of	NULL
the	NULL
mC1,4	NULL
oligonucleotide	NULL
with	NULL
BAL-17	NULL
nuclear	NULL
extract	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
after	NULL
incubation	NULL
with	NULL
the	NULL
indicated	NULL
compound	NULL
for	NULL
30	NULL
min	NULL
.	NULL

An	NULL
antibody	NULL
that	NULL
recognizes	NULL
all	NULL
CREBs	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
or	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
the	NULL
phosphorylated	NULL
CREB	NULL
(	NULL
lanes	NULL
P	NULL
)	NULL
was	NULL
added	NULL
prior	NULL
to	NULL
EMSA	NULL
as	NULL
indicated	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
CREB	NULL
was	NULL
phosphorylated	NULL
by	NULL
both	NULL
surface	NULL
Ig	NULL
receptor	NULL
cross-linking	NULL
and	NULL
PMA	NULL
,	NULL
we	NULL
performed	NULL
EMSA	NULL
with	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
phosphorylated	NULL
CREB	NULL
.	NULL

Figure	NULL
7D	NULL
demonstrates	NULL
that	NULL
very	NULL
little	NULL
phosphorylated	NULL
CREB	NULL
is	NULL
present	NULL
in	NULL
unstimulated	NULL
BAL-17	NULL
cells	NULL
.	NULL

Treatment	NULL
with	NULL
either	NULL
anti-IgM	NULL
or	NULL
PMA	NULL
led	NULL
to	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
complex	NULL
that	NULL
was	NULL
supershifted	NULL
with	NULL
the	NULL
antibody	NULL
specific	NULL
for	NULL
phosphorylated	NULL
CREB	NULL
(	NULL
Fig	NULL
.	NULL

7D	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
after	NULL
surface	NULL
Ig	NULL
cross-linking	NULL
is	NULL
mediated	NULL
by	NULL
PKC	NULL
and	NULL
the	NULL
phosphorylated	NULL
CREBs	NULL
activate	NULL
the	NULL
be/-2	NULL
promoter	NULL
.	NULL

BAL-17	NULL
cells	NULL
express	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
be/-2	NULL
,	NULL
so	NULL
we	NULL
wished	NULL
to	NULL
examine	NULL
the	NULL
up-regulation	NULL
of	NULL
be/-2	NULL
in	NULL
a	NULL
mature	NULL
B-cell	NULL
line	NULL
that	NULL
expressed	NULL
low	NULL
levels	NULL
of	NULL
be/-2	NULL
.	NULL

We	NULL
treated	NULL
the	NULL
DHL-9	NULL
cell	NULL
line	NULL
with	NULL
PMA	NULL
for	NULL
18	NULL
h	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
bel-2-luciferase	NULL
constructs	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
increased	NULL
by	NULL
ninefold	NULL
,	NULL
and	NULL
the	NULL
increase	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
CRE	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

As	NULL
was	NULL
the	NULL
case	NULL
for	NULL
BAL-17	NULL
cells	NULL
,	NULL
maximal	NULL
stimulation	NULL
required	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
URE	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
CREBs	NULL
in	NULL
DHL-9	NULL
nuclear	NULL
extracts	NULL
revealed	NULL
that	NULL
phosphorylation	NULL
on	NULL
serine	NULL
133	NULL
occurred	NULL
after	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
PMA	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
after	NULL
treatment	NULL
with	NULL
forskolin	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

As	NULL
was	NULL
the	NULL
case	NULL
with	NULL
BAL-17	NULL
cells	NULL
,	NULL
treatment	NULL
of	NULL
DHL-9	NULL
cells	NULL
with	NULL
forskolin	NULL
did	NULL
not	NULL
result	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
bel-2	NULL
promoter	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
further	NULL
demonstrate	NULL
the	NULL
importance	NULL
of	NULL
CREB	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
,	NULL
cotransfection	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
wild-type	NULL
CREB	NULL
expression	NULL
vector	NULL
or	NULL
a	NULL
dominant	NULL
negative	NULL
CREB	NULL
M1	NULL
expression	NULL
vector	NULL
.	NULL

The	NULL
dominant	NULL
negative	NULL
CREB	NULL
contains	NULL
an	NULL
alanine	NULL
at	NULL
position	NULL
133	NULL
and	NULL
can	NULL
not	NULL
be	NULL
phosphorylated	NULL
(	NULL
21	NULL
,	NULL
51	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8C	NULL
,	NULL
cotransfection	NULL
with	NULL
either	NULL
the	NULL
wild-type	NULL
CREB	NULL
or	NULL
CREB	NULL
M1	NULL
resulted	NULL
in	NULL
a	NULL
twofold	NULL
increase	NULL
in	NULL
the	NULL
constitutive	NULL
activity	NULL
of	NULL
the	NULL
bel-2	NULL
promoter	NULL
.	NULL

With	NULL
PMA	NULL
stimulation	NULL
,	NULL
there	NULL
was	NULL
a	NULL
slight	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
with	NULL
the	NULL
wild-type	NULL
CREB	NULL
construct	NULL
and	NULL
a	NULL
dramatic	NULL
decrease	NULL
with	NULL
the	NULL
CREB	NULL
M1	NULL
construct	NULL
.	NULL

These	NULL
changes	NULL
were	NULL
mediated	NULL
through	NULL
the	NULL
be	NULL
!	NULL

-2	NULL
CRE	NULL
site	NULL
,	NULL
because	NULL
there	NULL
was	NULL
no	NULL
change	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
construct	NULL
with	NULL
mutated	NULL
CRE	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
construct	NULL
with	NULL
two	NULL
CRE	NULL
sites	NULL
linked	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
showed	NULL
changes	NULL
similar	NULL
to	NULL
the	NULL
be/-2	NULL
promoter	NULL
when	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
I	NULL
>	NULL
Fold	NULL
Stimulation	NULL
by	NULL
PMA	NULL
0	NULL
Cont	NULL
.	NULL

WtURE/DRE	NULL
WtURE	NULL
MutCRE	NULL
O	NULL
1000	NULL
800	NULL
600	NULL
400	NULL
200	NULL
%	NULL
of	NULL
Basal	NULL
WtURE/DRE	NULL
0	NULL
1	NULL
:	NULL
i	NULL
os	NULL
pay	NULL
Cont	NULL
.	NULL

WT	NULL
___	NULL
M1	NULL
Cont	NULL
.	NULL

WT	NULL
M1	NULL
Wt	NULL
URE/DRE	NULL
MutCRE	NULL
INDUCTION	NULL
OF	NULL
be/-2	NULL
BY	NULL
CREB	NULL
PROTEINS	NULL
5553	NULL
Antibody	NULL
:	NULL
0	NULL
0	NULL
P	NULL
P	NULL
C	NULL
P	NULL
Forskolin	NULL
:	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-+	NULL
PMA	NULL
:	NULL
-	NULL
+	NULL
-	NULL
+	NULL
+	NULL
%	NULL
of	NULL
Basal	NULL
Activity	NULL
gus	NULL
ound	NULL
pound	NULL
U0	NULL
(	NULL
ae	NULL
-	NULL
Supershift	NULL
bnt	NULL
ug	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
1500	NULL
aa	NULL
ho	NULL
O	NULL
O	NULL
900	NULL
600	NULL
300	NULL
Cont	NULL
.	NULL

WT	NULL
___	NULL
M1	NULL
CRE	NULL
Cont	NULL
.	NULL

WT	NULL
_M1	NULL
ri	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Effect	NULL
of	NULL
PMA	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
bel-2	NULL
promoter	NULL
in	NULL
DHL-9	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Transient-transfection	NULL
analysis	NULL
with	NULL
the	NULL
basal	NULL
promoter	NULL
(	NULL
Cont	NULL
.	NULL
)	NULL

,	NULL
WiURE/DRE	NULL
,	NULL
WtDRE	NULL
,	NULL
WIURE	NULL
,	NULL
and	NULL
MutCRE	NULL
constructs	NULL
after	NULL
treatment	NULL
of	NULL
DHL-9	NULL
cells	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
for	NULL
18	NULL
h.	NULL
(	NULL
B	NULL
)	NULL
EMSA	NULL
of	NULL
the	NULL
mC1,4	NULL
oligonucleotide	NULL
with	NULL
DHL-9	NULL
nuclear	NULL
extract	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
after	NULL
incubation	NULL
with	NULL
the	NULL
indicated	NULL
compound	NULL
for	NULL
30	NULL
min	NULL
.	NULL

An	NULL
antibody	NULL
that	NULL
recognizes	NULL
all	NULL
CREBs	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
or	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
the	NULL
phosphorylated	NULL
CREB	NULL
(	NULL
lanes	NULL
P	NULL
)	NULL
was	NULL
added	NULL
prior	NULL
to	NULL
EMSA	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Cotransfection	NULL
experiments	NULL
in	NULL
DHL-9	NULL
cells	NULL
with	NULL
wild-type	NULL
CREB	NULL
and	NULL
CREB	NULL
M1	NULL
and	NULL
the	NULL
be/-2	NULL
promoter	NULL
constructs	NULL
WtURE/DRE	NULL
and	NULL
MutCRE	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
untreated	NULL
(	NULL
@	NULL
I	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
for	NULL
18	NULL
h	NULL
(	NULL
@	NULL
)	NULL
prior	NULL
to	NULL
harvesting	NULL
.	NULL

A	NULL
1-pg	NULL
portion	NULL
of	NULL
the	NULL
RSV	NULL
CREB	NULL
constructs	NULL
(	NULL
wild	NULL
type	NULL
[	NULL
WT	NULL
]	NULL
,	NULL
dominant	NULL
negative	NULL
mutant	NULL
(	NULL
M1	NULL
)	NULL
or	NULL
the	NULL
empty	NULL
expression	NULL
vector	NULL
(	NULL
Cont	NULL
.	NULL
)	NULL

and	NULL
10	NULL
jg	NULL
of	NULL
either	NULL
WtURE/DRE	NULL
or	NULL
MutCRE	NULL
were	NULL
used	NULL
in	NULL
each	NULL
transfection	NULL
experiment	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Cotransfection	NULL
experiments	NULL
in	NULL
DHL-9	NULL
cells	NULL
with	NULL
wild-type	NULL
CREB	NULL
and	NULL
CREB	NULL
M1	NULL
and	NULL
a	NULL
construct	NULL
with	NULL
two	NULL
CRE	NULL
sites	NULL
linked	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
(	NULL
CRE	NULL
)	NULL
or	NULL
two	NULL
#	NULL
1	NULL
sites	NULL
linked	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
(	NULL
#	NULL
1	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
untreated	NULL
(	NULL
MI	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
PMA	NULL
for	NULL
18	NULL
h	NULL
(	NULL
@	NULL
)	NULL
prior	NULL
to	NULL
harvesting	NULL
.	NULL

A	NULL
1-pg	NULL
portion	NULL
of	NULL
the	NULL
RSV	NULL
CREB	NULL
constructs	NULL
(	NULL
wild	NULL
type	NULL
[	NULL
WT	NULL
]	NULL
,	NULL
dominant	NULL
negative	NULL
mutant	NULL
[	NULL
M1	NULL
]	NULL
)	NULL
or	NULL
the	NULL
empty	NULL
expression	NULL
vector	NULL
(	NULL
Cont	NULL
.	NULL
)	NULL

and	NULL
10	NULL
ug	NULL
of	NULL
either	NULL
the	NULL
CRE	NULL
or	NULL
#	NULL
1	NULL
construct	NULL
were	NULL
used	NULL
in	NULL
each	NULL
transfection	NULL
experiment	NULL
.	NULL

The	NULL
basal	NULL
activity	NULL
of	NULL
each	NULL
promoter	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
empty	NULL
expression	NULL
vector	NULL
was	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
100.	NULL
wild-type	NULL
and	NULL
mutant	NULL
CREB	NULL
expression	NULL
vectors	NULL
were	NULL
cotransfected	NULL
(	NULL
Fig	NULL
.	NULL

8D	NULL
)	NULL
.	NULL

The	NULL
CRE	NULL
site	NULL
was	NULL
required	NULL
since	NULL
a	NULL
construct	NULL
with	NULL
two	NULL
#	NULL
1-binding	NULL
sites	NULL
showed	NULL
no	NULL
change	NULL
in	NULL
activity	NULL
with	NULL
cotransfection	NULL
of	NULL
either	NULL
wild-type	NULL
or	NULL
M1	NULL
CREB	NULL
(	NULL
Fig	NULL
.	NULL

8D	NULL
)	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
additional	NULL
support	NULL
for	NULL
the	NULL
role	NULL
of	NULL
phosphorylated	NULL
CREBs	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
during	NULL
B-cell	NULL
activation	NULL
.	NULL

We	NULL
also	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
bel-2	NULL
promoter	NULL
mediated	NULL
the	NULL
increase	NULL
in	NULL
be/-2	NULL
mRNA	NULL
that	NULL
is	NULL
seen	NULL
in	NULL
more	NULL
immature	NULL
B-cell	NULL
lines	NULL
that	NULL
are	NULL
rescued	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
anti-IgM	NULL
or	NULL
calcium	NULL
ionophores	NULL
.	NULL

Treatment	NULL
with	NULL
phorbol	NULL
esters	NULL
prevents	NULL
the	NULL
apoptosis	NULL
.	NULL

We	NULL
used	NULL
the	NULL
Epstein-Barr	NULL
virus-negative	NULL
Ramos	NULL
cell	NULL
line	NULL
to	NULL
avoid	NULL
the	NULL
confounding	NULL
effects	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
products	NULL
on	NULL
be/-2	NULL
expression	NULL
.	NULL

We	NULL
confirmed	NULL
by	NULL
several	NULL
different	NULL
techniques	NULL
including	NULL
cell	NULL
survival	NULL
and	NULL
DNA	NULL
fragmentation	NULL
analysis	NULL
that	NULL
ionomycin	NULL
caused	NULL
apoptosis	NULL
in	NULL
Ramos	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
PMA	NULL
protected	NULL
the	NULL
cells	NULL
from	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Ramos	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
be/-2	NULL
pro	NULL
moter-luciferase	NULL
constructs	NULL
and	NULL
treated	NULL
with	NULL
ionomycin	NULL
,	NULL
PMA	NULL
,	NULL
or	NULL
ionomycin	NULL
plus	NULL
PMA	NULL
for	NULL
6	NULL
h	NULL
before	NULL
being	NULL
harvested	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9C	NULL
,	NULL
treatment	NULL
with	NULL
PMA	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
resulted	NULL
in	NULL
a	NULL
12-fold	NULL
increase	NULL
in	NULL
be/-2	NULL
promoter	NULL
activity	NULL
.	NULL

There	NULL
was	NULL
no	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
if	NULL
the	NULL
CRE	NULL
site	NULL
was	NULL
mu-tated	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
treatment	NULL
of	NULL
Ramos	NULL
cells	NULL
with	NULL
PMA	NULL
resulted	NULL
in	NULL
phosphorylation	NULL
of	NULL
CREBs	NULL
at	NULL
serine	NULL
133	NULL
and	NULL
that	NULL
treatment	NULL
with	NULL
forskolin	NULL
had	NULL
a	NULL
smaller	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

9D	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
identified	NULL
the	NULL
major	NULL
positive	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
bei-2	NULL
promoter	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
demonstrated	NULL
that	NULL
a	NULL
CRE	NULL
site	NULL
mediates	NULL
both	NULL
basal	NULL
expression	NULL
and	NULL
induction	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
region	NULL
in	NULL
B	NULL
cells	NULL
following	NULL
activation	NULL
of	NULL
PKC	NULL
.	NULL

CREBs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
mediate	NULL
both	NULL
constitutive	NULL
and	NULL
kinase-inducible	NULL
gene	NULL
expression	NULL
(	NULL
29	NULL
,	NULL
44	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Although	NULL
negative	NULL
regulatory	NULL
elements	NULL
have	NULL
been	NULL
described	NULL
(	NULL
8	NULL
,	NULL
61	NULL
)	NULL
,	NULL
this	NULL
is	NULL
the	NULL
first	NULL
5554	NULL
WILSON	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
100	NULL
c	NULL
o	NULL
%	NULL
Viable	NULL
Cells	NULL
P3	NULL
&	NULL
O	NULL
[	NULL
Â«	NULL
]	NULL
ho	NULL
O	NULL
i	NULL
i	NULL
4	NULL
_	NULL
8	NULL
o	NULL
12	NULL
18	NULL
24	NULL
Hours	NULL
O	NULL
O	NULL
-	NULL
Â»	NULL
-	NULL
lon/PMA	NULL
-	NULL
Â»	NULL
-	NULL
PMA	NULL
-=-	NULL
lonomycin	NULL
-*-	NULL
Medium	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

D	NULL
15	NULL
3	NULL
[	NULL
LZ	NULL
Antibody	NULL
:	NULL
0	NULL
0	NULL
P	NULL
P	NULL
P	NULL
C	NULL
5	NULL
Forskolin	NULL
:	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+-212	NULL
DPMA	NULL
PMA	NULL
:	NULL
-	NULL
+	NULL
-~	NULL
+	NULL
-	NULL
+	NULL
5	NULL
,	NULL
ionomycin	NULL
5	NULL
mound	NULL
nsd	NULL
joed	NULL
WW	NULL
pros	NULL
(	NULL
h	NULL
-	NULL
Supershift	NULL
Â©	NULL
Bagi	NULL
a	NULL
wee	NULL
o	NULL
3	NULL
o	NULL
LL	NULL
o	NULL
0	NULL
Cont	NULL
.	NULL

WtURE/DRE	NULL
WiDRE	NULL
WIURE	NULL
MutCRE	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

PMA	NULL
treatment	NULL
of	NULL
Ramos	NULL
cells	NULL
leads	NULL
to	NULL
rescue	NULL
from	NULL
ionomycin-induced	NULL
apoptosis	NULL
and	NULL
up-regulation	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effect	NULL
of	NULL
1	NULL
pg	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
,	NULL
25	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
,	NULL
or	NULL
1	NULL
ag	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
plus	NULL
25	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
on	NULL
the	NULL
viability	NULL
of	NULL
Ramos	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Induction	NULL
of	NULL
apoptosis	NULL
in	NULL
Ramos	NULL
cells	NULL
at	NULL
12	NULL
h	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
medium	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
,	NULL
25	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
,	NULL
or	NULL
1	NULL
g	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
plus	NULL
25	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Transient-transfection	NULL
analysis	NULL
with	NULL
the	NULL
basal	NULL
promoter	NULL
(	NULL
Cont	NULL
.	NULL
)	NULL

,	NULL
WtURE/DRE	NULL
,	NULL
WiURE	NULL
,	NULL
WtDRE	NULL
,	NULL
and	NULL
MutCRE	NULL
constructs	NULL
after	NULL
treatment	NULL
of	NULL
Ramos	NULL
cells	NULL
with	NULL
1	NULL
g	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
,	NULL
25	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
,	NULL
or	NULL
1	NULL
pg	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
plus	NULL
25	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
for	NULL
6	NULL
h.	NULL
(	NULL
D	NULL
)	NULL
EMSA	NULL
of	NULL
the	NULL
mC1,4	NULL
oligonucleotide	NULL
with	NULL
Ramos	NULL
nuclear	NULL
extract	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
after	NULL
incubation	NULL
with	NULL
the	NULL
indicated	NULL
compound	NULL
for	NULL
30	NULL
min	NULL
.	NULL

An	NULL
antibody	NULL
that	NULL
recognizes	NULL
all	NULL
CREBs	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
or	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
the	NULL
phosphorylated	NULL
CREB	NULL
(	NULL
lanes	NULL
P	NULL
)	NULL
was	NULL
added	NULL
prior	NULL
to	NULL
EMSA	NULL
as	NULL
indicated	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
g	NULL
of	NULL
ionomycin	NULL
per	NULL
ml	NULL
,	NULL
an	NULL
identical	NULL
EMSA	NULL
pattern	NULL
was	NULL
obtained	NULL
.	NULL

report	NULL
of	NULL
a	NULL
positive	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
be/-2	NULL
promoter	NULL
.	NULL

The	NULL
constitutive	NULL
positive	NULL
region	NULL
is	NULL
active	NULL
in	NULL
both	NULL
pre-B	NULL
and	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
the	NULL
be/-2	NULL
promoter	NULL
is	NULL
repressed	NULL
in	NULL
pre-B	NULL
cells	NULL
by	NULL
#	NULL
1-binding	NULL
factors	NULL
and	NULL
that	NULL
expression	NULL
of	NULL
be/-2	NULL
is	NULL
low	NULL
in	NULL
pre-B	NULL
cells	NULL
(	NULL
8	NULL
)	NULL
.	NULL

We	NULL
describe	NULL
two	NULL
discrete	NULL
positive	NULL
regulatory	NULL
regions	NULL
,	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
URE	NULL
and	NULL
the	NULL
DRE	NULL
.	NULL

Our	NULL
preliminary	NULL
results	NULL
demonstrate	NULL
that	NULL
deletions	NULL
or	NULL
additions	NULL
of	NULL
sequence	NULL
between	NULL
the	NULL
two	NULL
sites	NULL
that	NULL
disrupt	NULL
the	NULL
helical	NULL
spacing	NULL
lead	NULL
to	NULL
loss	NULL
of	NULL
activity	NULL
.	NULL

Although	NULL
we	NULL
have	NULL
not	NULL
completed	NULL
the	NULL
characterization	NULL
of	NULL
the	NULL
URE	NULL
or	NULL
identified	NULL
the	NULL
transcription	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
URE	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
protein-protein	NULL
interactions	NULL
between	NULL
CREB	NULL
and	NULL
the	NULL
URE	NULL
factor	NULL
are	NULL
important	NULL
.	NULL

There	NULL
are	NULL
many	NULL
examples	NULL
of	NULL
interactions	NULL
between	NULL
two	NULL
regulatory	NULL
elements	NULL
that	NULL
can	NULL
be	NULL
destroyed	NULL
by	NULL
a	NULL
change	NULL
in	NULL
helical	NULL
spacing	NULL
(	NULL
27	NULL
,	NULL
46	NULL
,	NULL
49	NULL
,	NULL
55	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
CREB	NULL
interacts	NULL
with	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
an	NULL
adjacent	NULL
AP-1	NULL
site	NULL
in	NULL
a	NULL
manner	NULL
dependent	NULL
on	NULL
helical	NULL
spacing	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
results	NULL
of	NULL
in	NULL
vitro	NULL
methylation	NULL
analysis	NULL
revealed	NULL
that	NULL
the	NULL
bel-2	NULL
DRE	NULL
consisted	NULL
of	NULL
two	NULL
overlapping	NULL
sites	NULL
,	NULL
CREO	NULL
and	NULL
bCRE	NULL
.	NULL

Transient-transfection	NULL
analysis	NULL
revealed	NULL
that	NULL
the	NULL
bCRE	NULL
site	NULL
was	NULL
associated	NULL
with	NULL
most	NULL
of	NULL
the	NULL
activity	NULL
in	NULL
this	NULL
region	NULL
.	NULL

EMSA	NULL
with	NULL
transcription	NULL
factor	NULL
antibodies	NULL
,	NULL
UV	NULL
cross-linking	NULL
followed	NULL
by	NULL
SDS	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
and	NULL
het-erodimerization	NULL
with	NULL
a	NULL
truncated	NULL
CREB	NULL
were	NULL
performed	NULL
to	NULL
demonstrate	NULL
that	NULL
CREB	NULL
family	NULL
members	NULL
bind	NULL
to	NULL
the	NULL
bCRE	NULL
site	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
be/-2	NULL
promoter	NULL
implies	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
be/-2	NULL
expression	NULL
is	NULL
linked	NULL
to	NULL
a	NULL
signal	NULL
transduction	NULL
pathway	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

be/-2	NULL
induction	NULL
is	NULL
seen	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
with	NULL
activation	NULL
and	NULL
presumably	NULL
protects	NULL
the	NULL
cells	NULL
from	NULL
apoptosis	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
CREB	NULL
can	NULL
be	NULL
phosphorylated	NULL
and	NULL
transcriptionally	NULL
activated	NULL
by	NULL
PKC	NULL
(	NULL
59	NULL
)	NULL
.	NULL

PKC	NULL
phosphorylates	NULL
CREB	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
57	NULL
)	NULL
.	NULL

This	NULL
is	NULL
of	NULL
interest	NULL
because	NULL
it	NULL
may	NULL
represent	NULL
another	NULL
pathway	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
B	NULL
cells	NULL
.	NULL

Cross-linking	NULL
of	NULL
surface	NULL
Ig	NULL
results	NULL
in	NULL
transactivation	NULL
of	NULL
a	NULL
CRE-dependent	NULL
promoter-CAT	NULL
construct	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Agents	NULL
that	NULL
increase	NULL
cAMP	NULL
levels	NULL
did	NULL
not	NULL
activate	NULL
the	NULL
CRE-dependent	NULL
promoter	NULL
but	NULL
could	NULL
act	NULL
synergistically	NULL
with	NULL
cross-linking	NULL
of	NULL
surface	NULL
Ig	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
cross-linking	NULL
of	NULL
surface	NULL
Ig	NULL
receptor	NULL
on	NULL
mature	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
increased	NULL
be/-2	NULL
promoter	NULL
activity	NULL
through	NULL
a	NULL
PKC-dependent	NULL
pathway	NULL
involving	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

This	NULL
pathway	NULL
may	NULL
provide	NULL
a	NULL
mechanism	NULL
for	NULL
selection	NULL
of	NULL
long-lived	NULL
antigen-reactive	NULL
B	NULL
cells	NULL
by	NULL
coupling	NULL
antigen	NULL
recognition	NULL
to	NULL
protection	NULL
from	NULL
apoptosis	NULL
.	NULL

Reagents	NULL
that	NULL
in	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
crease	NULL
cAMP	NULL
levels	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
DRE	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
PMA	NULL
or	NULL
anti-Ig	NULL
M.	NULL
BAL-17	NULL
cells	NULL
are	NULL
derived	NULL
from	NULL
a	NULL
malignant	NULL
lymphoma	NULL
and	NULL
resemble	NULL
partially	NULL
activated	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

They	NULL
express	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
be/-2	NULL
constitutively	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
magnitude	NULL
of	NULL
induction	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
would	NULL
be	NULL
greater	NULL
in	NULL
B	NULL
cells	NULL
that	NULL
express	NULL
lower	NULL
levels	NULL
of	NULL
be/-2	NULL
such	NULL
as	NULL
resting	NULL
,	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
,	NULL
we	NULL
find	NULL
that	NULL
the	NULL
magnitude	NULL
of	NULL
induction	NULL
of	NULL
be/-2	NULL
expression	NULL
after	NULL
phorbol	NULL
ester	NULL
treatment	NULL
of	NULL
another	NULL
mature	NULL
B-cell	NULL
line	NULL
,	NULL
DHL-9	NULL
,	NULL
is	NULL
approximately	NULL
threefold	NULL
greater	NULL
than	NULL
that	NULL
seen	NULL
in	NULL
BAL-17	NULL
cells	NULL
.	NULL

A	NULL
dominant	NULL
negative	NULL
CREB	NULL
construct	NULL
interferes	NULL
with	NULL
the	NULL
PMA-induced	NULL
activation	NULL
of	NULL
the	NULL
bei-2	NULL
promoter	NULL
.	NULL

Cotransfection	NULL
of	NULL
a	NULL
wild-type	NULL
CREB	NULL
construct	NULL
increased	NULL
the	NULL
constitutive	NULL
activity	NULL
by	NULL
twofold	NULL
.	NULL

Stimulation	NULL
with	NULL
PMA	NULL
resulted	NULL
in	NULL
a	NULL
similar	NULL
increase	NULL
in	NULL
activity	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
whether	NULL
wild-type	NULL
CREB	NULL
was	NULL
cotransfected	NULL
or	NULL
not	NULL
.	NULL

Since	NULL
we	NULL
find	NULL
that	NULL
10	NULL
to	NULL
20	NULL
%	NULL
of	NULL
the	NULL
CREBs	NULL
present	NULL
in	NULL
DHL-9	NULL
cells	NULL
are	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
and	NULL
Western	NULL
blotting	NULL
data	NULL
[	NULL
not	NULL
shown	NULL
]	NULL
)	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
unphosphorylated	NULL
CREB	NULL
may	NULL
not	NULL
result	NULL
in	NULL
more	NULL
active	NULL
phosphorylated	NULL
CREB	NULL
.	NULL

Therefore	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
with	NULL
PMA	NULL
would	NULL
be	NULL
observed	NULL
.	NULL

The	NULL
dominant	NULL
negative	NULL
CREB	NULL
appears	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
function	NULL
of	NULL
the	NULL
phosphorylated	NULL
CREB	NULL
,	NULL
perhaps	NULL
by	NULL
forming	NULL
inactive	NULL
heterodimers	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
a	NULL
similar	NULL
signal	NULL
transduction	NULL
pathway	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
up-regulation	NULL
of	NULL
be/-2	NULL
expression	NULL
in	NULL
immature	NULL
B	NULL
cells	NULL
given	NULL
a	NULL
survival	NULL
signal	NULL
.	NULL

Treatment	NULL
of	NULL
Ramos	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
prevents	NULL
apoptosis	NULL
induced	NULL
by	NULL
ionomycin	NULL
or	NULL
by	NULL
surface	NULL
IgM	NULL
cross-linking	NULL
.	NULL

be/-2	NULL
mRNA	NULL
is	NULL
up-regulated	NULL
,	NULL
and	NULL
we	NULL
show	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
increases	NULL
by	NULL
12-fold	NULL
following	NULL
phorbol	NULL
ester	NULL
treatment	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
expression	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
CRE	NULL
site	NULL
in	NULL
the	NULL
bel-2	NULL
promoter	NULL
.	NULL

CREBs	NULL
in	NULL
phorbol	NULL
ester-treated	NULL
Ramos	NULL
cells	NULL
are	NULL
phosphorylated	NULL
by	NULL
a	NULL
pathway	NULL
involving	NULL
PKC	NULL
.	NULL

These	NULL
results	NULL
are	NULL
similar	NULL
to	NULL
those	NULL
found	NULL
in	NULL
mature	NULL
B	NULL
cell	NULL
lines	NULL
and	NULL
provide	NULL
a	NULL
demonstration	NULL
of	NULL
the	NULL
physiological	NULL
significance	NULL
of	NULL
signals	NULL
through	NULL
the	NULL
be/-2	NULL
promoter	NULL
CRE	NULL
site	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
CRE	NULL
site	NULL
mediates	NULL
the	NULL
PKC-dependent	NULL
increase	NULL
in	NULL
be/-2	NULL
levels	NULL
in	NULL
B	NULL
cells	NULL
at	NULL
two	NULL
different	NULL
stages	NULL
of	NULL
development	NULL
.	NULL

It	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
CRE	NULL
site	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
be/-2	NULL
induction	NULL
in	NULL
other	NULL
cells	NULL
in	NULL
which	NULL
Bcl-2	NULL
prevents	NULL
apoptosis	NULL
,	NULL
including	NULL
myeloid	NULL
,	NULL
breast	NULL
,	NULL
neural	NULL
,	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

Recent	NULL
data	NULL
have	NULL
demonstrated	NULL
that	NULL
phosphorylation	NULL
of	NULL
CREBs	NULL
during	NULL
T-cell	NULL
activation	NULL
occurs	NULL
in	NULL
a	NULL
cAMP-independent	NULL
manner	NULL
and	NULL
that	NULL
the	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
is	NULL
inhibited	NULL
by	NULL
rapamycin	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
be/-2	NULL
expression	NULL
is	NULL
inhibited	NULL
by	NULL
rapamycin	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Our	NULL
description	NULL
of	NULL
CRE	NULL
site	NULL
regulation	NULL
of	NULL
the	NULL
be/-2	NULL
promoter	NULL
suggests	NULL
that	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
rapamycin	NULL
on	NULL
be/-2	NULL
expression	NULL
may	NULL
be	NULL
due	NULL
to	NULL
its	NULL
interference	NULL
with	NULL
CREB	NULL
phosphorylation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Sim-ilarly	NULL
,	NULL
in	NULL
a	NULL
myeloid	NULL
cell	NULL
line	NULL
that	NULL
can	NULL
be	NULL
rescued	NULL
from	NULL
apoptosis	NULL
by	NULL
interleukin-3	NULL
,	NULL
the	NULL
interleukin-3	NULL
receptor	NULL
modulates	NULL
be/-2	NULL
mRNA	NULL
through	NULL
a	NULL
PKC-dependent	NULL
pathway	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
raise	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
PKC-CREB	NULL
pathway	NULL
we	NULL
have	NULL
identified	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
be/-2	NULL
mRNA	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
intriguing	NULL
to	NULL
speculate	NULL
that	NULL
CREBs	NULL
acting	NULL
through	NULL
the	NULL
CRE	NULL
site	NULL
serve	NULL
as	NULL
a	NULL
general	NULL
mechanism	NULL
for	NULL
coupling	NULL
surface	NULL
receptor	NULL
stimulation	NULL
to	NULL
protection	NULL
from	NULL
apoptosis	NULL
by	NULL
Bel-2	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grant	NULL
CA56764	NULL
and	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Baxter	NULL
Foundation	NULL
.	NULL

B.E.W	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
Physician	NULL
's	NULL
Research	NULL
Training	NULL
Award	NULL
0006	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
.	NULL

INDUCTION	NULL
OF	NULL
be/-2	NULL
BY	NULL
CREB	NULL
PROTEINS	NULL
5555	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Paul	NULL
Brindle	NULL
(	NULL
St.	NULL
Jude	NULL
Children	NULL
's	NULL
Research	NULL
Hos	NULL
pital	NULL
)	NULL
for	NULL
helpful	NULL
discussions	NULL
on	NULL
CREB	NULL
proteins	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

REFERENCES	NULL
.	NULL

Barton	NULL
,	NULL
K.	NULL
,	NULL
N.	NULL
Muthusamy	NULL
,	NULL
M.	NULL
Chanyangam	NULL
,	NULL
C.	NULL
Fischer	NULL
,	NULL
C.	NULL
Clendenin	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1996	NULL
.	NULL

Defective	NULL
thymocyte	NULL
proliferation	NULL
and	NULL
IL-1	NULL
production	NULL
in	NULL
transgenic	NULL
mice	NULL
expressing	NULL
a	NULL
dominant-negative	NULL
form	NULL
of	NULL
CREB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
379:81-85.	NULL
.	NULL

Bonnefoy-Berard	NULL
,	NULL
N.	NULL
,	NULL
L.	NULL
Genestier	NULL
,	NULL
M.	NULL
Flacher	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Revillard	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
phosphoprotein	NULL
phosphatase	NULL
calcineurin	NULL
controls	NULL
calcium-dependent	NULL
apoptosis	NULL
in	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:325-329.	NULL
.	NULL

Brunswick	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
E.	NULL
Samelson	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Mond	NULL
.	NULL

1991	NULL
.	NULL

Surface	NULL
immunoglob-	NULL
ulin	NULL
crosslinking	NULL
activates	NULL
a	NULL
tyrosine	NULL
kinase	NULL
pathway	NULL
in	NULL
B	NULL
cells	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:1311-1314.	NULL
.	NULL

Burkhardt	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
M.	NULL
Burnswick	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Bolen	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Mond	NULL
.	NULL

1991	NULL
.	NULL

Anti	NULL
immunoglobulin	NULL
stimulation	NULL
of	NULL
B	NULL
lymphocytes	NULL
activates	NULL
src-related	NULL
protein-tyrosine	NULL
kinases	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:7410-7414.	NULL
.	NULL

Cambier	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
L.	NULL
B.	NULL
Justement	NULL
,	NULL
K.	NULL
M.	NULL
Newell	NULL
,	NULL
Z	NULL
.	NULL

Z.	NULL
Chen	NULL
,	NULL
L.	NULL
K.	NULL
Harris	NULL
,	NULL
V.	NULL
M.	NULL
Sandoval	NULL
,	NULL
M.	NULL
G.	NULL
Klemsz	NULL
,	NULL
and	NULL
J.	NULL
T.	NULL
Ransom	NULL
.	NULL

1987	NULL
.	NULL

Transmembrane	NULL
signals	NULL
and	NULL
intracellular	NULL
``	NULL
second	NULL
messengers	NULL
``	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
quiescent	NULL
B	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

95:37-57.	NULL
.	NULL

Campbell	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Sefton	NULL
.	NULL

1990	NULL
.	NULL

Protein	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
induced	NULL
in	NULL
murine	NULL
B	NULL
lymphocytes	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
anti-immunoglobulin	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:2125-2131.	NULL
.	NULL

Chaouchi	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Vazquez	NULL
,	NULL
P.	NULL
Galanaud	NULL
,	NULL
and	NULL
C.	NULL
Leprince	NULL
.	NULL

1995	NULL
.	NULL

B	NULL
cell	NULL
antigen	NULL
receptor-mediated	NULL
apoptosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:3096-3104.	NULL
.	NULL

Chen	NULL
,	NULL
H.-M.	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Boxer	NULL
.	NULL

1995	NULL
.	NULL

#	NULL
1	NULL
binding	NULL
sites	NULL
are	NULL
negative	NULL
regulators	NULL
of	NULL
bel-2	NULL
expression	NULL
in	NULL
pre-B	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:3840-3847.	NULL
.	NULL

Chen	NULL
,	NULL
Z	NULL
.	NULL

Z.	NULL
,	NULL
K.	NULL
M.	NULL
Coggeshall	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Cambier	NULL
.	NULL

1986	NULL
.	NULL

Translocation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
during	NULL
membrane	NULL
immunoglobulin-mediated	NULL
transmembrane	NULL
signaling	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

136:2300-2304	NULL
.	NULL

Chiles	NULL
,	NULL
T.	NULL
C	NULL
,	NULL
,	NULL
J.	NULL
Liu	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1991	NULL
.	NULL

Cross-linking	NULL
of	NULL
surface	NULL
Ig	NULL
receptors	NULL
on	NULL
murine	NULL
B	NULL
lymphocytes	NULL
stimulates	NULL
the	NULL
expression	NULL
of	NULL
nuclear	NULL
tetradecanoyl	NULL
phorbol	NULL
acetate-response	NULL
element-binding	NULL
proteins	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:1730-1735	NULL
.	NULL

Chodosh	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

1988	NULL
.	NULL

UV	NULL
crosslinking	NULL
of	NULL
proteins	NULL
to	NULL
nucleic	NULL
acids	NULL
,	NULL
p.	NULL
12.5.1-12.5.6	NULL
.	NULL

In	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Chomezynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
N.	NULL
Sacchi	NULL
.	NULL

1986	NULL
.	NULL

Single	NULL
step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acidic	NULL
guanidinium	NULL
thiocyanate	NULL
phenol	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162	NULL
;	NULL
156-159	NULL
.	NULL

Cohen	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

1991	NULL
.	NULL

Programmed	NULL
cell	NULL
death	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Adv	NULL
.	NULL

Immunol	NULL
.	NULL

50:55-85	NULL
.	NULL

Cuende	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
E.	NULL
Ales-Martinez	NULL
,	NULL
L.	NULL
Ding	NULL
,	NULL
M.	NULL
Gonzalez-Garcia	NULL
,	NULL
C	NULL
.	NULL

Martinez-A	NULL
.	NULL

,	NULL
and	NULL
G.	NULL
Nunez	NULL
.	NULL

1993	NULL
.	NULL

Programmed	NULL
cell	NULL
death	NULL
by	NULL
bel-2-dependent	NULL
and	NULL
independent	NULL
mechanisms	NULL
in	NULL
B	NULL
lymphoma	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:1555-1560	NULL
.	NULL

Feuerstein	NULL
,	NULL
N.	NULL
,	NULL
D.	NULL
Huago	NULL
,	NULL
S.	NULL
H.	NULL
Hinrichs	NULL
,	NULL
D.	NULL
J.	NULL
Orten	NULL
,	NULL
N.	NULL
Aiyar	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
cAMP-responsive	NULL
enhancer	NULL
binding	NULL
proteins	NULL
during	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
by	NULL
IL-2	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:68-79	NULL
.	NULL

Forsgren	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Suedjelund	NULL
,	NULL
and	NULL
H.	NULL
Wigzell	NULL
.	NULL

1976	NULL
.	NULL

Lymphocyte	NULL
stimulation	NULL
by	NULL
protein	NULL
A	NULL
of	NULL
Staphylococcus	NULL
aureus	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

6207-213	NULL
.	NULL

Gauss	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Lieber	NULL
.	NULL

1992	NULL
.	NULL

DEAE-dextran	NULL
enhances	NULL
electroporation	NULL
of	NULL
mammalian	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:6739-6740	NULL
.	NULL

Genestier	NULL
,	NULL
L.	NULL
,	NULL
N.	NULL
Bonnefoy-Berard	NULL
,	NULL
J.-P.	NULL
Rouault	NULL
,	NULL
M.	NULL
Flacher	NULL
,	NULL
and	NULL
J.-P.	NULL
Revillard	NULL
.	NULL

1995	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-	NULL
Â«	NULL
up-regulates	NULL
Bcl-2	NULL
expression	NULL
and	NULL
decreases	NULL
calcium-dependent	NULL
apoptosis	NULL
in	NULL
human	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

7533-540	NULL
.	NULL

Gold	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
J.	NULL
P.	NULL
Jakway	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
DeFranco	NULL
.	NULL

1987	NULL
.	NULL

Involvement	NULL
of	NULL
a	NULL
guanine	NULL
nucleotide-binding	NULL
component	NULL
in	NULL
membrane	NULL
Ig	NULL
M-stimulated	NULL
phos-phoinositide	NULL
breakdown	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

139:3604-3613	NULL
.	NULL

Gold	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

Law	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
DeFranco	NULL
.	NULL

1990	NULL
.	NULL

Stimulation	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
the	NULL
B-lymphocyte	NULL
antigen	NULL
receptor	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
345:810-813	NULL
.	NULL

Gonzalez	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1989	NULL
.	NULL

Cyclic	NULL
AMP	NULL
stimulates	NULL
somatostatin	NULL
gene	NULL
tranciption	NULL
by	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
.	NULL

Cell	NULL
59:675-680	NULL
.	NULL

Graninger	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
M.	NULL
Seto	NULL
,	NULL
B.	NULL
Boutain	NULL
,	NULL
P.	NULL
Goldman	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1987	NULL
.	NULL

Expression	NULL
of	NULL
bel-2	NULL
and	NULL
bel-2-Ig	NULL
fusion	NULL
transcripts	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

80:1512-1515	NULL
.	NULL

Gregory	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
C.	NULL
Dive	NULL
,	NULL
S.	NULL
Henderson	NULL
,	NULL
C.	NULL
A.	NULL
Smith	NULL
,	NULL
G.	NULL
T.	NULL
Williams	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
genes	NULL
protects	NULL
human	NULL
B	NULL
cells	NULL
from	NULL
death	NULL
by	NULL
apoptosis	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
349:612-614	NULL
.	NULL

Hanson	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
J.	NULL
L	NULL
Grisolana	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Ley	NULL
.	NULL

1993	NULL
.	NULL

Consensus	NULL
AP-1	NULL
and	NULL
CRE	NULL
motifs	NULL
upstream	NULL
from	NULL
the	NULL
human	NULL
cytotoxic	NULL
serine	NULL
protease	NULL
B	NULL
(	NULL
CSP-B/	NULL
CGL-1	NULL
)	NULL
gene	NULL
synergize	NULL
to	NULL
activate	NULL
transcription	NULL
.	NULL

Blood	NULL
82:2749-2757	NULL
.	NULL

Harnett	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
G.	NULL
G.	NULL
B.	NULL
Klaus	NULL
.	NULL

1988	NULL
.	NULL

G	NULL
protein	NULL
coupling	NULL
of	NULL
antigen	NULL
receptor-stimulated	NULL
polyphosphoinositide	NULL
hydrolysis	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

140:3135-3139	NULL
.	NULL

Hartley	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
M.	NULL
P.	NULL
Cooke	NULL
,	NULL
D.	NULL
A.	NULL
Fulcher	NULL
,	NULL
A.	NULL
W.	NULL
Harris	NULL
,	NULL
S.	NULL
Cory	NULL
,	NULL
A.	NULL
Basten	NULL
,	NULL
and	NULL
C.	NULL
C.	NULL
Goodnow	NULL
.	NULL

1993	NULL
.	NULL

Elimination	NULL
of	NULL
self-reactive	NULL
B	NULL
lymphocytes	NULL
pro	NULL
5556	NULL
27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

WILSON	NULL
ET	NULL
AL	NULL
.	NULL

ceeds	NULL
in	NULL
two	NULL
stages	NULL
:	NULL
arrested	NULL
development	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
72:325-335	NULL
.	NULL

Huang	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
K.	NULL
T.	NULL
Jeang	NULL
.	NULL

1993	NULL
.	NULL

Increased	NULL
spacing	NULL
between	NULL
Sp1	NULL
and	NULL
TATAA	NULL
renders	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
defective	NULL
:	NULL
implications	NULL
for	NULL
Tat	NULL
function	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:6937-6944	NULL
.	NULL

Knox	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
M.	NULL
Finney	NULL
,	NULL
A.	NULL
E.	NULL
Milner	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
M.	NULL
J.	NULL
O.	NULL
Wakelam	NULL
,	NULL
R.	NULL
H.	NULL
Vichell	NULL
,	NULL
and	NULL
J.	NULL
Gordon	NULL
.	NULL

1992	NULL
.	NULL

Second-messenger	NULL
pathways	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
survival	NULL
in	NULL
germinal-centre	NULL
B	NULL
cells	NULL
and	NULL
in	NULL
Burkitt	NULL
lymphoma	NULL
lines	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
52:959-966	NULL
.	NULL

Krajewski	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
W.	NULL
Lee	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
monomeric	NULL
derivative	NULL
of	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
CREB	NULL
functions	NULL
as	NULL
a	NULL
constitutive	NULL
activator	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:7204-7210	NULL
.	NULL

Lalli	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
P.	NULL
Sassone-Corsi	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transduction	NULL
and	NULL
gene	NULL
regula-tion	NULL
:	NULL
the	NULL
nuclear	NULL
response	NULL
to	NULL
cAMP	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:17359-17362	NULL
.	NULL

Lane	NULL
,	NULL
P.	NULL
J.	NULL
L.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
R.	NULL
M.	NULL
McConnell	NULL
,	NULL
K.	NULL
Draves	NULL
,	NULL
J.	NULL
Deans	NULL
,	NULL
G.	NULL
L.	NULL
Schieven	NULL
,	NULL
and	NULL
E.	NULL
A.	NULL
Clark	NULL
,	NULL
1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
signal	NULL
transduction	NULL
through	NULL
surface	NULL
Ig	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146	NULL
:	NULL
715-722	NULL
.	NULL

Lee	NULL
,	NULL
K.	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
N.	NULL
Masson	NULL
.	NULL

1993	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
by	NULL
CREB	NULL
and	NULL
its	NULL
relatives	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1174:221-233	NULL
.	NULL

Levy	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
J.-C.	NULL
Brouet	NULL
.	NULL

1994	NULL
.	NULL

Interleukin-10	NULL
prevents	NULL
spontancous	NULL
death	NULL
of	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
by	NULL
induction	NULL
of	NULL
the	NULL
bel-2	NULL
protein	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

93:424-428	NULL
.	NULL

Liu	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
C.	NULL
Chiles	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1991	NULL
.	NULL

Inducible	NULL
nuclear	NULL
expression	NULL
of	NULL
NF-kB	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
stimulated	NULL
through	NULL
the	NULL
surface	NULL
Ig	NULL
receptor	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:1685-1691	NULL
.	NULL

Liu	NULL
,	NULL
Y.-J	NULL
.	NULL

,	NULL
D.	NULL
Y.	NULL
Mason	NULL
,	NULL
G.	NULL
D.	NULL
Johnson	NULL
,	NULL
S.	NULL
Abbot	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
D.	NULL
L.	NULL
Hardie	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
and	NULL
I.	NULL
C.	NULL
M.	NULL
MacLennan	NULL
.	NULL

1991	NULL
.	NULL

Germinal	NULL
center	NULL
cells	NULL
express	NULL
bel-2	NULL
protein	NULL
after	NULL
activation	NULL
by	NULL
signals	NULL
which	NULL
prevent	NULL
their	NULL
entry	NULL
into	NULL
apoptosis	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21:1905-1910	NULL
.	NULL

Meyer	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1993	NULL
.	NULL

Cyclic	NULL
adenosine	NULL
3',5'-monophos-phate	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
and	NULL
related	NULL
transcription-activating	NULL
deoxyribonucleic	NULL
acid-binding	NULL
proteins	NULL
.	NULL

Endocr	NULL
.	NULL

Rev	NULL
.	NULL

14:269-290	NULL
.	NULL

Miyashita	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Harigai	NULL
,	NULL
M.	NULL
Hanada	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Reed	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
p53-dependent	NULL
negative	NULL
response	NULL
element	NULL
in	NULL
the	NULL
be/-2	NULL
gene	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:3131-3135	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
Z.~-J	NULL
.	NULL

Liu	NULL
,	NULL
A.	NULL
Kawahara	NULL
,	NULL
Y.	NULL
Tsujimoto	NULL
,	NULL
E.	NULL
L.	NULL
Barsoumian	NULL
,	NULL
R.	NULL
M.	NULL
Perlmutter	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1995	NULL
.	NULL

Three	NULL
distinct	NULL
IL-2	NULL
signaling	NULL
pathways	NULL
mediated	NULL
by	NULL
bel-2	NULL
,	NULL
c-myc	NULL
and	NULL
Ick	NULL
cooperate	NULL
in	NULL
hematopoietic	NULL
cell	NULL
proliferation	NULL
.	NULL

Cell	NULL
81:223-231	NULL
.	NULL

Monroe	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
and	NULL
S.	NULL
Haldar	NULL
,	NULL
1989	NULL
.	NULL

Involvement	NULL
of	NULL
a	NULL
specific	NULL
guanine	NULL
nucleotide	NULL
binding	NULL
protein	NULL
in	NULL
receptor	NULL
immunoglobulin	NULL
stimulated	NULL
inositol	NULL
phospholipid	NULL
hydrolysis	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1013:273-278	NULL
.	NULL

Montminy	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
K.	NULL
A.	NULL
Sevarino	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Wagner	NULL
,	NULL
G.	NULL
Mandel	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Goodman	NULL
.	NULL

1986	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
cyclic-AMP-responsive	NULL
element	NULL
within	NULL
the	NULL
rat	NULL
somatostatin	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:6682-6686	NULL
.	NULL

Negrini	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
Silini	NULL
,	NULL
C.	NULL
Kozak	NULL
,	NULL
Y.	NULL
Tsujimoto	NULL
,	NULL
and	NULL
C.	NULL
Croce	NULL
.	NULL

1987	NULL
.	NULL

Molecular	NULL
analysis	NULL
of	NULL
mbcl-2	NULL
:	NULL
structure	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
murine	NULL
gene	NULL
homologous	NULL
to	NULL
the	NULL
human	NULL
gene	NULL
involved	NULL
in	NULL
follicular	NULL
lymphoma	NULL
.	NULL

Cell	NULL
49:455-463	NULL
.	NULL

Ning	NULL
,	NULL
Z.-Q	NULL
.	NULL

,	NULL
J.	NULL
D.	NULL
Norton	NULL
,	NULL
D.	NULL
Johnson	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Murphy	NULL
.	NULL

1995	NULL
.	NULL

Early	NULL
gene	NULL
signalling-dependent	NULL
and	NULL
-independent	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
Ramos	NULL
human	NULL
B	NULL
cells	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
over-expression	NULL
of	NULL
bel-2	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

215:23-29	NULL
.	NULL

Parnes	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Seidman	NULL
.	NULL

1982	NULL
.	NULL

Structure	NULL
of	NULL
wild-type	NULL
and	NULL
mutant	NULL
beta	NULL
2-microglobulin	NULL
genes	NULL
.	NULL

Cell	NULL
29:661-669	NULL
.	NULL

Quinn	NULL
,	NULL
P.	NULL
G.	NULL
1993	NULL
.	NULL

Distinct	NULL
activation	NULL
domains	NULL
within	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
mediate	NULL
basal	NULL
and	NULL
cAMP-stimulated	NULL
tran	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

scription	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:16999-17009	NULL
.	NULL

Reed	NULL
,	NULL
J.	NULL
,	NULL
Y.	NULL
Tsujimoto	NULL
,	NULL
J.	NULL
D.	NULL
Alpers	NULL
,	NULL
C.	NULL
M.	NULL
Croce	NULL
,	NULL
and	NULL
P.	NULL
C.	NULL
Nowell	NULL
.	NULL

1987	NULL
.	NULL

Regulation	NULL
of	NULL
bel-2	NULL
proto-oncogene	NULL
expression	NULL
during	NULL
normal	NULL
human	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

Science	NULL
236:1295-1298	NULL
.	NULL

Reith	NULL
,	NULL
W.	NULL
,	NULL
C.	NULL
A.	NULL
Siegrist	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
E.	NULL
Barras	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1994	NULL
.	NULL

Function	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
promoters	NULL
requires	NULL
cooperative	NULL
binding	NULL
between	NULL
RFX	NULL
and	NULL
NF-Y	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:554-558	NULL
.	NULL

Rinaudo	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
K.	NULL
Su	NULL
,	NULL
L.	NULL
A.	NULL
Falk	NULL
,	NULL
S.	NULL
Haldar	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Mufson	NULL
.	NULL

1995	NULL
.	NULL

Human	NULL
interleukin-3	NULL
receptor	NULL
modulates	NULL
be/-2	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
through	NULL
protein	NULL
kinase	NULL
C	NULL
in	NULL
TF-1	NULL
cells	NULL
.	NULL

Blood	NULL
86:80-88	NULL
.	NULL

Romagnani	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
G.	NULL
Gindizi	NULL
,	NULL
R.	NULL
Biagiotti	NULL
,	NULL
F.	NULL
Almerigona	NULL
,	NULL
E.	NULL
Maggi	NULL
,	NULL
G.	NULL
Del	NULL
Prete	NULL
,	NULL
and	NULL
M.	NULL
Ricci	NULL
.	NULL

1981	NULL
.	NULL

Surface	NULL
immunoglobulins	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
interaction	NULL
of	NULL
protein	NULL
A	NULL
with	NULL
human	NULL
B	NULL
cells	NULL
and	NULL
in	NULL
the	NULL
triggering	NULL
of	NULL
B	NULL
cell	NULL
proliferation	NULL
induced	NULL
by	NULL
protein	NULL
A-containing	NULL
Staphylococcus	NULL
aureus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

127:1307-1313	NULL
.	NULL

Schanke	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
and	NULL
B.	NULL
G.	NULL
Van	NULL
Ness	NULL
.	NULL

1994	NULL
.	NULL

Organization	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
kappa	NULL
Ig	NULL
intron	NULL
enhancer	NULL
.	NULL

Effects	NULL
of	NULL
position	NULL
,	NULL
orientation	NULL
,	NULL
and	NULL
spacing	NULL
,	NULL
J.	NULL
Immunol	NULL
.	NULL

153:4564-4572	NULL
.	NULL

Seto	NULL
,	NULL
M.	NULL
,	NULL
U.	NULL
Jaeger	NULL
,	NULL
R.	NULL
D.	NULL
Hockett	NULL
,	NULL
W.	NULL
Graninger	NULL
,	NULL
S.	NULL
Bennett	NULL
,	NULL
P.	NULL
Goldman	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1988	NULL
.	NULL

Alternative	NULL
promoters	NULL
and	NULL
exons	NULL
,	NULL
somatic	NULL
mutation	NULL
and	NULL
deregulation	NULL
of	NULL
the	NULL
Bel-2-Ig	NULL
fusion	NULL
gene	NULL
in	NULL
lymphoma	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7123-131	NULL
.	NULL

Struthers	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
W.	NULL
W.	NULL
Vale	NULL
,	NULL
C.	NULL
Arias	NULL
,	NULL
P.	NULL
E.	NULL
Sawchenko	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1991	NULL
.	NULL

Somatotroph	NULL
hypoplasia	NULL
and	NULL
dwarfism	NULL
in	NULL
transgenic	NULL
mice	NULL
expressing	NULL
a	NULL
non-phosphorylatable	NULL
CREB	NULL
mutant	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
350:622-624	NULL
.	NULL

Tsubata	NULL
,	NULL
T.	NULL
,	NULL
J.	NULL
Wu	NULL
,	NULL
and	NULL
T.	NULL
Honjo	NULL
.	NULL

1993	NULL
.	NULL

B-cell	NULL
apoptosis	NULL
induced	NULL
by	NULL
antigen	NULL
receptor	NULL
crosslinking	NULL
is	NULL
blocked	NULL
by	NULL
a	NULL
T-cell	NULL
signal	NULL
through	NULL
CD40	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
364:645-648	NULL
.	NULL

Valentine	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Licciardi	NULL
.	NULL

1992	NULL
.	NULL

Rescue	NULL
from	NULL
anti-IgM-induced	NULL
programmed	NULL
cell	NULL
death	NULL
by	NULL
the	NULL
B	NULL
cell	NULL
surface	NULL
proteins	NULL
CD20	NULL
and	NULL
CD40	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22:3141-3148	NULL
.	NULL

Venkataraman	NULL
,	NULL
L.	NULL
,	NULL
D.	NULL
A.	NULL
Francis	NULL
,	NULL
Z.	NULL
Wang	NULL
,	NULL
J.	NULL
Liu	NULL
,	NULL
T.	NULL
L.	NULL
Rothstein	NULL
,	NULL
and	NULL
R.	NULL
Sen.	NULL
1994	NULL
.	NULL

Cyclosporin-A	NULL
sensitive	NULL
induction	NULL
of	NULL
NF-AT	NULL
in	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

Immunity	NULL
1:189-196	NULL
.	NULL

Wang	NULL
,	NULL
G.	NULL
,	NULL
H.	NULL
I.	NULL
Yeh	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Lin	NULL
.	NULL

1994	NULL
.	NULL

Characterization	NULL
of	NULL
cis-regulating	NULL
elements	NULL
and	NULL
trans-activating	NULL
factors	NULL
of	NULL
the	NULL
rat	NULL
cardiac	NULL
troponin	NULL
T	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:30595-30603	NULL
.	NULL

Xie	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
C.	NULL
Chiles	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1993	NULL
.	NULL

Induction	NULL
of	NULL
CREB	NULL
activity	NULL
via	NULL
the	NULL
surface	NULL
Ig	NULL
receptor	NULL
of	NULL
B	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:880-889	NULL
.	NULL

Xie	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
mediates	NULL
activation	NULL
of	NULL
nuclear	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
in	NULL
B	NULL
lymphocytes	NULL
stimulated	NULL
through	NULL
surface	NULL
Ig	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:1717-1723	NULL
.	NULL

Xing	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Quinn	NULL
.	NULL

1994	NULL
.	NULL

Three	NULL
distinct	NULL
regions	NULL
within	NULL
the	NULL
constitutive	NULL
activation	NULL
domain	NULL
of	NULL
cAMP	NULL
regulatory	NULL
element-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
are	NULL
required	NULL
for	NULL
transcription	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:28723-28736	NULL
.	NULL

Yamamoto	NULL
,	NULL
K.	NULL
K.	NULL
,	NULL
G.	NULL
A.	NULL
Gonzalez	NULL
,	NULL
W.	NULL
H.	NULL
I.	NULL
Biggs	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1988	NULL
.	NULL

Phosphorylation-induced	NULL
binding	NULL
and	NULL
transcriptional	NULL
efficacy	NULL
of	NULL
nuclear	NULL
factor	NULL
CREB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
334:494-498	NULL
.	NULL

Yamanashi	NULL
,	NULL
U.	NULL
,	NULL
Y.	NULL
Fukui	NULL
,	NULL
B.	NULL
W	NULL
t	NULL
,	NULL
U.	NULL
Kinoshita	NULL
,	NULL
Y.	NULL
Ichimori	NULL
,	NULL
K.	NULL
Toyoshima	NULL
,	NULL
and	NULL
T.	NULL
Yamamoto	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
Src-like	NULL
protein	NULL
kinase	NULL
Lyn	NULL
and	NULL
its	NULL
association	NULL
with	NULL
phosphatidylinositol	NULL
3-kinase	NULL
upon	NULL
B-cell	NULL
antigen	NULL
receptor-mediated	NULL
signaling	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1118-1122	NULL
.	NULL

Young	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
negative	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
bel-2	NULL
5'-untranslated	NULL
region	NULL
inhibits	NULL
expression	NULL
from	NULL
an	NULL
upstream	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:3686-3697	NULL
.	NULL

